Papyriferic acid derivatives as reversal agents of multidrug resistance in cancer cells

Article abstract of DOI:10.1016/j.bmc.2010.02.046

Forty-one derivatives of papyriferic acid were prepared based on our previous finding that methyl papyriferate (3) showed potent reversing effect on cytotoxicity of colchicine against multidrug resistance (MDR) human cancer cells (KB-C2), and evaluated fo

Full text of DOI:10.1016/j.bmc.2010.02.046

Bioorganic & Medicinal Chemistry 18 (2010) 2964–2975
Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier.com/locate/bmc
Papyriferic acid derivatives as reversal agents of multidrug resistance
in cancer cells
b
c
Juan Xiong a, Masatoshi Taniguchi a, Yoshiki Kashiwada a, , Michiko Sekiya , Takashi Yamagishi ,
*
Yoshihisa Takaishi a
a Graduate School of Pharmaceutical Sciences, University of Tokushima, Tokushima 770-8505, Japan
b Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata 956-8603, Japan
c Kitami Institute of Technology, Kitami, Hokkaido 090-8507, Japan
a r t i c l e i n f o
a b s t r a c t
Article history:
Forty-one derivatives of papyriferic acid were prepared based on our previous finding that methyl papy-
riferate (3) showed potent reversing effect on cytotoxicity of colchicine against multidrug resistance
(MDR) human cancer cells (KB-C2), and evaluated for their cytotoxicity and effect on reversing P-gp-med-
Received 27 January 2010
Revised 18 February 2010
Accepted 18 February 2010
Available online 6 March 2010
iated MDR against KB-C2 cells. 3-O-(Morpholino-b-oxopropanoyl)-12b-acetoxy-3
(20S,24R)-epoxydammarane (37) significantly increased the sensitivity of colchicine against KB-C2 cells
by 185-fold at 5 g/mL (7.4 M), and the cytotoxicity of colchicine was recovered to nearly that of sen-
a,25-dihydroxy-
l
l
Keywords:
sitive (KB) cells. The other several new amide derivatives also exhibited potent reversal activity compa-
rable to or more potent than methyl papyriferate and verapamil.
Ó 2010 Elsevier Ltd. All rights reserved.
Papyriferic acid
Betula platyphylla var. japonica
P-Glycoprotein
MDR
1. Introduction
uate P-gp function,13 or induced unfavourable pharmacokinetic
interactions,14,15 resulting in failure in their clinical trials. Although
Multidrug resistance (MDR) is one of the major impediments to
effective cancer chemotherapy. A primary mechanism of MDR is
due to the overexpression of ATP-binding cassette (ABC) transport-
ers, which efflux a broad class of anticancer drugs, remarkably
decreasing cellular drug accumulation.1 So far, at least 12 ABC
transporters from four ABC subfamilies have been identified to
play important roles in the drug resistance of cancer cells.2 Among
them, P-glycoprotein (P-gp, also known as ABCB1 or MDR1), a
member of the ABCB subfamily, is the most crucial and well-stud-
ied ABC transporter.3–6 Many structurally unrelated anticancer
drugs used clinically, such as vinca alkaloids, anthracyclines, epip-
odophyllotoxins, and taxanes, are known to be P-gp substrates.7,8
P-gp-mediated drug transport could be inhibited or altered by a
wide range of agents (efflux blockers, chemosensitizers, MDR-
reversal agents, MDR-modulators, or MDR-inhibitors).2,9,10 Verapa-
mil, the calcium channel blocker, was the first discovered P-gp
modulator.11,12 Since then, various reversal agents were brought
to light, including the first generation inhibitors (e.g., amiodarone,
cyclosporine, quinidine, nifedipine), the second generation inhibi-
tors (e.g., PSC-833, dexverapamil) and the third generation modu-
lators (e.g., VX-710, LY335979, XR-9576).13 However, these
compounds were ineffective or toxic at the doses required to atten-
progress in the development of ideal P-gp inhibitors has been slow,
it is believed that this approach is still realistic and promising for
overcoming MDR.
In our previous research for plant-derived MDR-reversal agents,
methyl papyriferate (3), isolated from the floral spikes of Betula
platyphylla var. japonica, demonstrated potent reversing effect on
the cytotoxicity of colchicine against MDR human cancer cells
(KB-C2) at 8.1 lM, which was comparable to 5 l
M verapamil.16
In contrast, papyriferic acid (1) did not enhance the cytotoxicity
of colchicine against KB-C2 cells. These findings prompt our mod-
ification of papyriferic acid as new MDR-reversal agents. This paper
describes the preparation of forty-one derivatives of papyriferic
acid, as well as its related triterpene, and evaluation of their cyto-
toxicities and MDR-reversing effect against KB-C2 cells.
2. Results and discussion
2.1. Chemistry
Although compounds 1 and 2 (3-O-malonyl-epiocotillol-II),
both of which containing a 3-O-carboxyacetyl group, did not show
MDR-reversing effect, a great enhanced MDR-reversal effect was
observed in their methyl esters (compounds 3 and 4, respectively)
in our previous research (Fig. 1). These results suggested that
the ester group at C-3 position of methyl papyriferate played an
* Corresponding author. Tel./fax: +81 88 633 7276.
E-mail address: kasiwada@ph.tokukshima-u.ac.jp (Y. Kashiwada).
0968-0896/$ - see front matter Ó 2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2010.02.046

J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
2965
26
HO
HO
O
27
25
R
O
H
NH2
26
27
28
30
37
38
R2
O20
O
H
H
12
NHCH3
NHC2H5
NHC4H9
Morpholino
N(CH3)2
21
17
19
18
a
1
9
1
O
O
O
O
H
3
5
30
R
O
R1O
O
H
H
28 29
26 – 28, 30, 37 – 38
papyriferic acid (1) R1=H, R2=OAc
3-O-malonyl-epiocotillol-II (2) R1=H, R2=H
Scheme 3. Reagents and conditions: (a) DCC, HOBt, CH2Cl2, rt.
methyl papyriferate (3) R1=CH3, R2=OAc
3-O-methylmalonyl-epiocotillol-II (4) R1=CH3, R2=H
catalysts afforded compounds 26–28, 30, 37, and 38 with satisfac-
tory yields.
Figure 1. Structure of papyriferic acid and its analogues.
The structures of all the compounds are confirmed by 1H NMR,
13C NMR, 2D NMR (HMBC&HSQC) and MS spectroscopic analyses.
important role for MDR-reversing effect. Based on this finding, var-
ious alkyl substituents were introduced to the carboxylic acid group
of the malonyl moiety in compounds 1 and 2. In addition, the alkylc-
arbamoyl derivatives of papyriferic acid were also prepared, and
evaluated their cytotoxicity as well as MDR-reversing effects.
Compounds 5–14 and 17–23 were prepared by treatment of
compounds 1 and 2 with appropriate alkyl bromides in the pres-
ence of K2CO3. In contrast, compounds 15,16, 24 and 25 were syn-
thesized by reaction of acyl chloride of 1 or 2 with appropriate
alcohols in the presence of NEt3 (Scheme 1).
The amide derivatives of papyriferic acid were synthesized as
outlined in Schemes 2 and 3. Thus, papyriferic acid was treated
with oxalyl dichloride, and then reacted with appropriate amines
yielding the desired derivatives. However, compounds 39–45 were
also produced unexpectedly as a by-product in each case, resulting
in low yield of the desired amide derivatives. In contrast, reaction
of papyriferic acid with appropriate amines using DCC and HOBt as
2.2. Biological evaluation
The cytotoxic activities of compounds 3–45 against human epi-
dermoid nasopharyngeal carcinoma cell lines, KB (drug-sensitive
cells) and KB-C2 (colchicine-resistant KB cells), were evaluated. Re-
sults are summarized in Table 1.
All the tested compounds showed little or no antiproliferative
effects against KB and KB-C2 cell lines (IC50 values greater than
25 lM). No remarkable differences were found in the cytotoxic
activities between the sensitive and resistant cell lines, except for
compounds 6–8, 13, 14, 16, and 32. However, some of them exhib-
ited enhanced cytotoxicity against KB-C2 cells in the presence of
2.5 lM colchicine, which had no effect on the growth of KB-C2
cells. This suggested that these analogues might show some
MDR-reversing effects.
R2
C2H5
C3H7
C4H9
C5H11
5, 17
6, 18
7, 19
8, 20
9, 21
10, 22
11, 23
12
HO
O
HO
O
R1
R1
H
H
C6H
13
C7H
a or b
15
C8H
17
O
O
O
O
H
H
CH2CH=CH2
C(CH3)3
CH2Ph
CH(CH3)2
CH2CH(CH3)2
R2O
O
HO
O
H
H
13
14
15, 24
16, 25
1: R1 = OAc
2: R1 = H
R1 = OAc
5–16:
17–25: R1 = H
Scheme 1
Scheme 1. Reagents and conditions: (a) RBr, K2CO3, acetone, rt; (b) (COCl)2, CH2Cl2, rt; then ROH, NEt3, CH2Cl2, rt.
O
RHN
O
R
C3H7
C5H11
C9H19
CH2Ph
HO
O
O
O
O
29, 39
31, 40
32, 41
33, 42
34, 43
35, 44
36, 45
O
H
O
O
H
H
a
1
Ph
O
O
O
O
H
H
2,5-dimethoxyl Ph
C(CH3)3
RHN
O
RHN
O
H
29, 31–36
39–45
Scheme 2. Reagents and conditions: (a) (COCl)2, CH2Cl2, reflux; (b) then RNH2, CH2Cl2 or benzene, reflux.

2966
J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
Table 1
Cytotoxicity (IC50 in
a
lM) of compounds 3–45 against KB and KB-C2 cell lines (with or without colchicine) in vitro
Compound
KB
KB-C2
KB-C2 (+2.5
lM colchicine)
Compound
KB
KB-C2
KB-C2 (+2.5 lM colchicine)
3
5
6
7
8
26.7 2.1
39.1 1.8
27.8 1.2
40.8 1.5
45.4 2.8
70.7 5.7
>100
32.1 0.80
64.3 2.7
67.8 2.3
>100
>100
>100
>100
>100
48.3 0.89
>100
>100
>100
>100
56.6 1.8
>100
>100
>100
>100
>100
>100
2.5 0.09
23.1 0.28
24.3 0.53
52.3 1.8
>100
>100
>100
>100
14.9 0.40
51.4 1.0
>100
41.4 1.2
44.1 0.79
7.5 0.64
41.9 1.0
66.1 0.98
>100
>100
>100
>100
>100
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
39.3 1.8
40.9 2.3
39.7 2.8
46.1 1.0
24.9 1.2
38.3 0.82
42.8 2.4
31.9 1.1
28.3 1.7
>100
40.5 0.72
30.8 0.57
25.2 1.3
24.8 0.75
>100
43.7 0.30
43.1 0.80
43.9 0.67
40.8 0.68
24.4 0.42
38.3 0.76
>100
33.2 0.77
26.2 0.64
>100
47.9 1.4
27.5 0.48
28.0 0.56
26.6 1.0
>100
3.8 0.38
1.9 0.04
1.9 0.03
5.6 0.13
4.8 0.07
12.2 0.49
>100
7.0 0.43
4.9 0.01
26.3 0.51
11.5 0.13
1.3 0.07
1.2 0.11
5.4 0.12
>100
>100
>100
>100
>100
29.2 1.3
18.3 0.74
—
9
10
11
12
13
14
15
16
4
17
18
19
20
21
22
23
24
25
>100
34.8 2.2
31.5 1.5
43.7 2.7
74.6 2.7
33.3 2.1
45.4 2.3
>100
60.3 2.6
>100
>100
>100
>100
>100
>100
>100
>100
>100
>100
42
43
44
45
>100
>100
>100
>100
>100
>100
>100
>100
>100
Daunorubicin
Colchicine
Verapamil
0.64 0.03
0.013 0.0001
ND
16.2 0.98
10.9 0.60
>100
96.5 0.98
>100
97.0 5.8
3.0 0.11
a
Data are mean SE from three or four experiments.
Among the ester derivatives (3, 5–16), methyl papyriferate (3)
showed the most enhanced cytotoxicity in the presence of
2.5 M colchicine with an IC50 value of 2.5 M, which was 13-
fold reversal effect as compared with its cytotoxicity (IC50
32.1 M) against KB-C2. The reversing activity was reduced
according to the chain length, and the reversing activity was to-
tally lost when the alkyl group with the chain length of more
than five or benzyl group was introduced (8–11 and 14). This
tendency was also observed in the 3-epiocotillol derivatives (4,
17–25), although their potency were less than those found in al-
kyl papyriferate. This result suggested that the length of alkyl
chain as well as the acetoxy group at C-12 plays an important
role for the reversing activity.
their reversal effects, which were over 20-fold in each case, as com-
pared with their cytotoxicities against KB-C2 cells, were more po-
tent than that of methyl papyriferate. The other amide derivatives,
except for 32, also showed moderate MDR-reversing activities;
their reversal effects ranged from 11- to 3-fold. In overall, the
reversing activities of the amide derivatives were more potent than
the corresponding ester derivatives. In contrast, the 25-O-alkylcar-
bamoyl formate of the amide derivatives, except for 39 and 45, did
not show cytotoxicity whether colchicine was present or absent,
although the corresponding amide derivatives showed weak
reversing effect. Compounds 39 and 45 also showed less potent
reversing activities than those of the corresponding amide deriva-
tives. These data implied that the free hydroxyl group at C-25 is
also important for the reversing activity.
l
l
l
In the case of the amide derivatives, compounds 27, 28, 37, and
38 demonstrated the significantly enhanced cytotoxicity in the
Compounds 3, 4, 26–28, and 36–39 were selected to determine
the recovery of the cytotoxicity of colchicine against KB-C2 cells
(Table 2). Compound 37 demonstrated the most potent reversal ef-
presence of 2.5
lM colchicine with IC50 values ranging from
1.2 M to 1.9 M, which were more potent than those of verapamil
l
l
(IC50 3.1
lM) and methyl papyriferate (IC50 2.5
lM). In addition,
fect of colchicine resistance of KB-C2 cells. Thus, 5 lg/mL of 37
Table 2
M) of colchicine against KB-C2 cells and physico-chemical propertiesb of indicated compounds
a
MDR-reversing effects on the cytotoxicity (IC50 in
l
Compound
IC50 value of colchicine (
g/mL
7.2 0.18 (1.5)c
l
M)
No. H
Acceptors
MW
MV
TPSA
Log P (ACD)
0
1
l
5
l
g/mL
Donors
3
4
26
27
28
36
37
38
0.21 0.009 (51.6)
0.74 0.024 (14.8)
0.22 0.006 (49.3)
0.15 0.003 (74.4)
0.20 0.007 (53.9)
1.1 0.088 (9.8)
8
6
8
8
8
8
9
8
11
1
1
2
2
2
2
1
1
2
619
561
604
618
632
660
674
632
759
610
566
596
613
630
663
662
630
748
108.4
82.1
7.3
8.3
6.5
6.7
7.2
7.9
7.4
7.0
8.5
10.0 0.29 (1.1)
5.3 0.19 (2.1)
2.3 0.12 (4.7)
4.2 0.026 (2.6)
9.6 0.19 (1.1)
0.63 0.065 (17.4)
4.5 0.24 (2.4)
9.3 0.21 (1.2)
125.1
111.2
111.2
111.2
111.6
102.4
146.3
0.059 0.003 (185.4)
0.12 0.001 (87.5)
0.16 0.004 (68.8)
39
Colchicine
10.9 0.60 (1.0)
Verapamild
1
2
5
l
l
l
M
M
M
6.4 0.11 (1.7)
2.8 0.12 (3.9)
0.37 0.007 (29.9)
a
b
c
Data are mean SE from three or four experiments.
Physico-chemical parameters were calculated using ACD softwares.
Fold-reversion, was calculated by dividing the corresponding IC50 value with the IC50 value of colchicine (10.9
Positive control.
lM).
d

J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
2967
reversed the cytotoxicity of colchicine against KB-C2 cells from the
IC50 value of 10.9 to 0.059 M, in which the sensitivity of colchi-
cine against KB-C2 was increased by 185-fold. It is worthy to note
that compound 37 reversed the resistance of colchicine against KB-
C2 cells to almost sensitive cells (KB cells) level, since the IC50 value
Optical rotations were measured with a JASCO DIP-370 digital
polarimeter. NMR (400 MHz for 1H, 100 MHz for 13C, using TMS
as internal standard) was recorded on a Bruker AVANCE 400 spec-
trometer. HRESIMS was obtained on a Waters LCT Premier. Column
chromatography was performed with silica gel 60 N (63–210 nm,
Merck); Preparative HPLC was carried out on Mightysil Si 60
(250 ꢀ 20 mm id).
l
of colchicine against KB cells was 0.013
of colchicine resistance was also observed at 1
trast, 5 g/mL of compounds 26–28, 38, and 39 increased sensitiv-
l
M. The 17-fold recovery
lg/mL of 37. By con-
l
ity of colchicine by ranging from 87- to 49-fold, which were
4.2. Chemical preparation
comparable to or slightly more potent than methyl papyriferate
(5
l
g/mL) and verapamil (5
lM), while compounds 4 and 36 only
Papyriferic acid (3-O-malonyl-12b-acetoxy-3a,25-dihydroxy-
showed moderate reversal effect even at highest concentration.
Several important physico-chemical properties were calculated
to consider structure–activity relationships (SARs) in our deriva-
tives. All the compounds shown in Table 2 are lipophilic with the
octanol/water partition coefficient (log P) in the range of 6.5–8.5,
strong H-bond acceptors (6–11 H-bond acceptors), and possess a
molecular weight in the range of 560–759. Their physico-chemical
properties are in good agreement with those previously reported
MDR-reversing agents.13,17–20 The log P value was shown to be in-
creased according to the chain length of the alkyl group in both es-
ter and amide derivatives (data not shown), which was well
correlated with the potency of their reversing activity. In contrast,
the acetoxy group at C-12 in papyriferic acid was found to be
functionalized as two hydrogen acceptors by comparison of the
properties between 3 and 4. The lack of this group led to increasing
the log P value, which was also correlated with the decrease of the
reversing activity. However, the other correlations between the
MDR-reversing effect and calculated physico-chemical properties
were complex and multifunctional similar to those observed in
other SAR studies of P-gp modulators.19–21
(20S,24R)-epoxydammarane 1) and 12-deacetoxy papyriferic acid
(3-O-malonyl-epiocotillol-II 2).
These triterpenes used in this work were separated from the flo-
ral spikes of B. platyphylla var. japonica by reported procedures.16
The 1H and 13C spectral data correspond with that previously
reported.22,23
4.2.1. General procedure for preparation of ester analogues (5–
16, 17–25)
Method A: A solution of 1 or 2 (50–60 mg, 1 equiv), an appropri-
ate bromide (1.1–5 equiv, but30 equiv for 13) and K2CO3 (2–3 equiv,
but 16 equiv for 13) in anhydrous acetone (3 mL) was refluxed at
60 °C overnight with stirring. After removal of the inorganic salts
by filtration, the filtrate was concentrated under reduced pressure
to dryness. The oily residue was chromatographed over a silica gel
column (hexane/ethyl acetate 10:1) and further purified by semi-
preparative HPLC (hexane/acetone/2-propanol 4:1:0.01) to afford
the desired compounds.
Method B: To a solution of 1 or 2 (50–60 mg, 1 equiv) in CH2Cl2
(2 mL), oxalyl dichloride (2.0 M solution in CH2Cl2, 2.5 equiv) was
added with stirring. The mixture was stirred at room temperature
for 3 h, and then CH2Cl2 was evaporated to dryness. The residue
was dissolved in CH2Cl2 (3 mL) and then isopropanol or isobutanol
(3 equiv) and NEt3 (2.5 equiv) were added. The reaction mixture
was left standing overnight at room temperature. The reaction
mixture was diluted with CHCl3 and washed three times with
water. The organic layer was dried over anhydrous Na2SO4 and
concentrated under reduced pressure to give an oily residue. The
residue was subjected to silica gel column chromatography and
semi-preparative HPLC to yield pure product.
3. Conclusions
Based on our previous finding that methyl papyriferate (3)
showed potent reversing effect on cytotoxicity of colchicine against
MDR human cancer cells (KB-C2), forty-one analogues of papyriferic
acid were prepared and evaluated their cytotoxicity and MDR-
reversing effect against cancer cell lines. All the investigated
compounds showed little or no antiproliferative effect, and the cyto-
toxicity of several analogues was enhanced in the presence of non-
toxic concentration of colchicine. Among the alkyl papyriferate
derivatives, methyl papyriferate (3) showed the most enhanced
4.2.1.1. 3-O-Ethylmalonyl-12b-acetoxy-3a,25-dihydroxy-(20S,24R)-
epoxydammarane (5). Yield 29.1% (starting with 50 mg of 1 by
cytotoxicity in the presence of 2.5 lM colchicine, and the enhance-
method A); colorless oil; ½a D29
ꢁ
ꢂ18.5 (c 0.83, CHCl3). 1H NMR
ment of the cytotoxicity was decreased according to the chain length
of the alkyl group. Removal of 12-acetoxy group of the alkyl papyrif-
erate derivatives reduced their reversal effect. The amide derivatives
of papyriferic acid demonstrated more potent activity than the alkyl
papyriferate. However, the 25-O-alkylcarbamoyl formate of the
amide derivatives were less potent. Furthermore, the recovery of
the cytotoxicity of colchicine against KB-C2 cells by compounds 3,
4, 26–28, and 36–39 were assessed. Compound 37 significantly re-
(CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-19),
0.88 (3H, s, CH3-29), 0.96 (3H, s, CH3-30), 0.99 (3H, s, CH3-18),
1.09 (3H, s, CH3-27), 1.17 (3H, s, CH3-21), 1.24 (3H, s, CH3-26),
1.27 (3H, t, J = 6.8, CH3-Et), 2.01 (3H, s, CH3-Ac), 3.40 (2H, s, malo-
nyl –CH2–), 3.65 (1H, dd, J = 6.8, 7.2 Hz, H-24), 4.21 (2H, q, J = 6.8,
CH2-Et), 4.68 (1H, br s, H-3), 4.83 (1H, dt, J = 5.2, 10.4 Hz, H-12);
13C NMR (CDCl3, 100 MHz) d 14.2(CH3-Et), 15.5 (C-18), 15.8
(C-19), 17.6 (C-30), 18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3
(C-21), 22.6 (C-2), 24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.6
(C-26), 27.9 (C-28), 28.2 (C-11),31.2 (C-15), 34.0 (C-1), 34.3 (C-7),
36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 42.1 (malonyl
–CH2–), 46.2 (C-13), 49.6 (C-9), 50.4 (C-17), 50.7 (C-5), 52.3
(C-14), 61.5 (COO-CH2), 71.0 (C-25), 75.5 (C-12), 79.7 (C-3), 83.3
(C-24), 85.7 (C-20), 166.1 (malonyl –CO–), 169.7 (malonyl –CO–),
170.5 (Ac, –CO–). HRESIMS (positive) m/z 655.4165 [M+Na]+ (calcd
for C37H60O8Na, 655.4186).
versed the resistance of colchicine against KB-C2 cells at 5 lg/mL.
It increased the sensitivity of colchicine against KB-C2 cells by
185-fold, and thus the cytotoxicity of colchicine was recovered to
nearly that of sensitive cells. These analogues appear to be potential
candidates of MDR-reversing agents in cancer cells and, studies of
the effect of these analogues on P-gp functions are in progress.
4. Experimental section
4.1. General procedures
4.2.1.2. 3-O-Propylmalonyl-12b-acetoxy-3a,25-dihydroxy-(20S,
24R)-epoxydammarane (6). Yield 65.1% (starting with 55 mg of 1
by method A); colorless oil; ½a D29
ꢁ
ꢂ16.0 (c 3.53, CHCl3). 1H NMR
Unless otherwise indicated, all reagents were purchased from
commercial suppliers and are used without further purification.
(CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-19),

2968
J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
0.88 (3H, s, CH3-29), 0.96 (3H, s, CH3-30), 0.96 (3H, t, J = 6.8,
CH3-30), 0.99 (3H, s, CH3-18), 1.09 (3H, s, CH3-27), 1.17 (3H, s,
CH3-21), 1.18 (3H, s, CH3-26), 1.67 (2H, hex, J = 6.8, CH2-20), 2.00
(3H, s, CH3-Ac), 3.40 (2H, s, malonyl –CH2–), 3.65 (1H, dd, J = 6.4,
6.8 Hz, H-24), 4.21 (2H, t, J = 6.8, CH2-10), 4.68 (1H, br s, H-3),
4.83 (1H, dt, J = 5.2, 10.4 Hz, H-12); 13C NMR (CDCl3, 100 MHz) d
10.3 (C-30), 15.5 (C-18), 15.8 (C-19), 17.7 (C-30), 18.0 (C-6), 21.6
(C-29), 21.9 (Ac, –CH3), 21.9 (C-20), 22.2 (C-21), 22.6 (C-2), 24.2
(C-27), 26.1 (C-23), 26.7 (C-16), 27.5 (C-26), 27.8 (C-28), 28.2
(C-11),31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1 (C-10),
38.8 (C-22), 39.8 (C-8), 42.0 (malonyl –CH2–), 46.2 (C-13), 49.6
(C-9), 50.4 (C-17), 50.6 (C-5), 52.2 (C-14), 67.0 (C-10), 71.0 (C-25),
75.4 (C-12), 79.6 (C-3), 83.3 (C-24), 85.7 (C-20), 166.1 (malonyl
–CO–), 166.7 (malonyl –CO–), 170.5 (Ac, –CO–). HRESIMS (positive)
m/z 669.4333 [M+Na]+ (calcd for C38H62O8Na, 669.4342).
dd, J = 6.4, 6.8 Hz, H-24), 4.11 (2H, t, J = 6.8, CH2-10), 4.68 (1H, br
s, H-3), 4.83 (1H, dt, J = 5.2, 10.8 Hz, H-12); 13C NMR (CDCl3,
100 MHz) d 14.0 (C-60), 15.6 (C-18), 15.9 (C-19), 17.7 (C-30), 18.0
(C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.5 (C-50), 22.7
(C-2), 24.2 (C-27), 25.5 (C-40), 26.1 (C-23), 26.8 (C-16), 27.6 (C-
26), 27.9 (C-28), 28.3 (C-11), 28.5 (C-30), 31.3 (C-15), 31.4 (C-20),
34.0 (C-1), 34.4 (C-7), 36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8
(C-8), 42.0 (malonyl –CH2–), 46.3 (C-13), 49.6 (C-9), 50.5 (C-17),
50.7 (C-5), 52.3 (C-14), 65.7 (C-10), 71.0 (C-25), 75.5 (C-12), 79.6
(C-3), 83.4 (C-24), 85.7 (C-20), 166.1 (malonyl –CO–), 166.8 (malo-
nyl –CO–), 170.5 (Ac, –CO–). HRESIMS (positive) m/z 711.4794
[M+Na]+ (calcd for C41H68O8Na, 711.4812).
4.2.1.6. 3-O-Heptylmalonyl-12b-acetoxy-3a,25-hydroxy-(20S,24R)-
epoxydammarane (10). Yield 64.7% (starting with 59 mg of 1 by
method A); colorless oil; ½a D28
ꢁ
ꢂ17.3 (c 4.21, CHCl3). 1H NMR
4.2.1.3. 3-O-Butylmalonyl-12b-acetoxy-3a,25-dihydroxy-(20S,24R)-
(CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-19),
0.88 (3H, s, CH3-29), 0.87 (3H, t, J = 6.8, CH3-70), 0.96 (3H, s,
CH3-30), 0.99 (3H, s, CH3-18), 1.09 (3H, s, CH3-27), 1.17 (3H, s,
CH3-21), 1.18 (3H, s, CH3-26), 1.25–1.30 (6H, m, CH2-40, 50, 60),
1.64 (4H, m, CH2-20, 30), 2.00 (3H, s, CH3-Ac), 3.40 (2H, s, malonyl
–CH2–), 3.65 (1H, dd, J = 6.8, 7.2 Hz, H-24), 4.14 (2H, t, J = 6.8,
CH2-10), 4.68 (1H, br s, H-3), 4.83 (1H, dt, J = 5.2, 10.4 Hz, H-12);
13C NMR (CDCl3, 100 MHz) d 14.0 (C-70), 15.5 (C-18), 15.8 (C-19),
17.7 (C-30), 18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.2 (C-21),
22.5 (C-60), 22.6 (C-2), 24.2 (C-27), 25.7 (C-50), 26.0 (C-23), 26.7
(C-16), 27.5 (C-26), 27.8 (C-28), 28.2 (C-11), 28.4 (C-40), 28.8 (C-
30), 31.2 (C-15), 31.6 (C-20), 34.0 (C-1), 34.4 (C-7), 36.7 (C-4), 37.0
(C-10), 38.8 (C-22), 39.7 (C-8), 42.0 (malonyl –CH2–), 46.2 (C-13),
49.6 (C-9), 50.4 (C-17), 50.6 (C-5), 52.2 (C-14), 65.6 (C-10), 71.0
(C-25), 75.4 (C-12), 79.6 (C-3), 83.4 (C-24), 85.7 (C-20), 166.1 (mal-
onyl –CO–), 166.7 (malonyl –CO–), 170.4 (Ac, –CO–). HRESIMS
(positive) m/z 725.4953 [M+Na]+ (calcd for C42H70O8Na, 725.4968).
epoxydammarane (7). Yield 40.7% (starting with 54 mg of 1 by
method A); colorless oil; ½a D29
ꢁ
ꢂ16.2 (c 2.20, CHCl3). 1H NMR
(CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-19),
0.88 (3H, s, CH3-29), 0.93 (3H, t, J = 7.2, CH3-40), 0.96 (3H, s,
CH3-30), 0.99 (3H, s, CH3-18), 1.09 (3H, s, CH3-27), 1.17 (3H, s,
CH3-21), 1.20 (3H, s, CH3-26), 1.40 (2H, m, CH2-30), 1.63 (2H, m,
CH2-20), 2.00 (3H, s, CH3-Ac), 3.40 (2H, s, malonyl –CH2–), 3.65
(1H, dd, J = 6.8, 7.2 Hz, H-24), 4.16 (2H, t, J = 6.8, CH2-10), 4.68
(1H, br s, H-3), 4.83 (1H, dt, J = 5.2, 10.8 Hz, H-12); 13C NMR (CDCl3,
100 MHz) d 13.6 (C-40), 15.5 (C-18), 15.8 (C-19), 17.7 (C-30), 18.0
(C-6), 19.0 (C-30), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.6
(C-2), 24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-26), 27.8
(C-28), 28.2 (C-11), 30.5 (C-20), 31.2 (C-15), 34.0 (C-1), 34.3 (C-7),
36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 42.0 (malonyl
–CH2–), 46.2 (C-13), 49.6 (C-9), 50.4 (C-17), 50.7 (C-5), 52.3 (C-
14), 65.3 (C-10), 71.0 (C-25), 75.4 (C-12), 79.6 (C-3), 83.3 (C-24),
85.7 (C-20), 166.1 (malonyl –CO–), 166.7 (malonyl –CO–), 170.5
(Ac, –CO–). HRESIMS (positive) m/z 683.4485 [M+Na]+ (calcd for
C39H64O8Na, 683.4499).
4.2.1.7. 3-O-Octylmalonyl-12b-acetoxy-3a,25-dihydroxy-(20S,
24R)-epoxydammarane (11). Yield 65.1% (starting with 55 mg of
1 by method A); colorless oil; ½a D28
ꢁ
ꢂ12.1 (c 4.09, CHCl3). 1H NMR
4.2.1.4. 3-O-Pentylmalonyl-12b-acetoxy-3
a
,25-dihydroxy-(20S,
(CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-19),
0.88 (3H, s, CH3-29), 0.87 (3H, t, J = 6.8, CH3-80), 0.96 (3H, s,
CH3-30), 0.99 (3H, s, CH3-18), 1.09 (3H, s, CH3-27), 1.17 (3H, s,
CH3-21), 1.18 (3H, s, CH3-26), 1.27–1.30 (8H, m, CH2-40, 50,60,70),
1.64 (4H, m, CH2-20, 30), 2.00 (3H, s, CH3-Ac), 3.40 (2H, s, malonyl
–CH2–), 3.65 (1H, dd, J = 6.8, 7.2 Hz, H-24), 4.14 (2H, t, J = 6.8,
CH2-10), 4.68 (1H, br s, H-3), 4.83 (1H, dt, J = 5.2, 10.8 Hz, H-12);
13C NMR (CDCl3, 100 MHz) d 14.0 (C-80), 15.5 (C-18), 15.8 (C-19),
17.7 (C-30), 18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21),
22.6 (C-70), 22.6 (C-2), 24.2 (C-27), 25.8 (C-60), 26.1 (C-23), 26.7
(C-16), 27.5 (C-26), 27.8 (C-28), 28.2 (C-11), 28.5 (C-50), 29.1 (C-
30, 40), 31.2 (C-15), 31.7 (C-20), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4),
37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 42.0 (malonyl –CH2–), 46.2
(C-13), 49.6 (C-9), 50.4 (C-17), 50.6 (C-5), 52.2 (C-14), 65.7 (C-10),
71.0 (C-25), 75.4 (C-12), 79.6 (C-3), 83.4 (C-24), 85.7 (C-20),
166.1 (malonyl –CO–), 166.7 (malonyl –CO–), 170.4 (Ac, –CO–).
HRESIMS (positive) m/z 739.5125 [M+Na]+ (calcd for C43H72O8Na,
739.5125).
24R)-epoxydammarane (8). Yield 27.7% (starting with 55 mg of 1
by method A); colorless oil; ½a D28
ꢁ
ꢂ14.6 (c 5.05, CHCl3). 1H NMR
(CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-19),
0.88 (3H, s, CH3-29), 0.88 (3H, t, J = 6.8, CH3-50), 0.96 (3H, s,
CH3-30), 0.99 (3H, s, CH3-18), 1.09 (3H, s, CH3-27), 1.17 (3H, s,
CH3-21), 1.19 (3H, s, CH3-26), 1.33 (2H, m, CH2-40), 1.64 (4H, m,
CH2-30, 20), 2.00 (3H, s, CH3-Ac), 3.40 (2H, s, malonyl –CH2–), 3.65
(1H, dd, J = 6.0, 6.4 Hz, H-24), 4.14 (2H, t, J = 6.8, CH2-10), 4.68
(1H, br s, H-3), 4.83 (1H, dt, J = 5.2, 10.8 Hz, H-12); 13C NMR (CDCl3,
100 MHz) d 13.9 (C-50), 15.6 (C-18), 15.9 (C-19), 17.7 (C-30), 18.0
(C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.3 (C-40), 22.7
(C-2), 24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.6 (C-26), 27.9 (C-
28), 28.3 (C-11), 27.9 (C-30), 28.2 (C-20), 31.2 (C-15), 34.0 (C-1),
34.4 (C-7), 36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 42.0
(malonyl –CH2–), 46.3 (C-13), 49.6 (C-9), 50.5 (C-17), 50.7 (C-5),
52.3 (C-14), 69.2 (C-10), 71.0 (C-25), 75.5 (C-12), 79.7 (C-3), 83.4
(C-24), 85.8 (C-20), 166.1 (malonyl –CO–), 166.8 (malonyl –CO–),
170.5 (Ac, –CO–). HRESIMS (positive) m/z 697.4629 [M+Na]+ (calcd
for C40H66O8Na, 697.4655).
4.2.1.8. 3-O-Allylmalonyl-12b-acetoxy-3a,25-dihydroxy-(20S,24R)-
epoxydammarane (12). Yield 85.0% (starting with 60 mg of 1 by
4.2.1.5. 3-O-Hextylmalonyl-12b-acetoxy-3
20S,24R)-epoxydammarane (9). Yield 51.2% (starting with 55 mg
a
,25-dihydroxy-(17S,
method A); colorless oil; ½a D28
ꢁ
ꢂ16.4 (c 4.65, CHCl3). 1H NMR
(CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-19),
0.88 (3H, s, CH3-29), 0.96 (3H, s, CH3-30), 0.99 (3H, s, CH3-18),
1.09 (3H, s, CH3-27), 1.17 (3H, s, CH3-21), 1.18 (3H, s, CH3-26),
2.01 (3H, s, CH3-Ac), 3.44 (2H, s, malonyl –CH2–), 3.65 (1H, dd,
J = 7.6, 6.4 Hz, H-24), 4.65 (2H, d, J = 6.0, CH2-10), 4.68 (1H, br s,
H-3), 4.83 (1H, dt, J = 5.2, 10.8 Hz, H-12), 5.29 (1H, dd, J = 1.2,
10.4, CH2-30), 5.36 (1H, dd, J = 1.2, 15.2, CH2-30), 5.93 (1H, ddt,
of 1 by method A); colorless oil; ½a D28
ꢁ
ꢂ15.1 (c 3.02, CHCl3). 1H NMR
(CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-19), 0.88
(3H, s, CH3-29), 0.88 (3H, t, J = 6.8, CH3-60), 0.96 (3H, s, CH3-30),
0.99 (3H, s, CH3-18), 1.09 (3H, s, CH3-27), 1.17 (3H, s, CH3-21),
1.18 (3H, s, CH3-26), 1.29 (4H, m, CH2-40, 50), 1.65 (4H, m, CH2-20,
30), 2.00 (3H, s, CH3-Ac), 3.40 (2H, s, malonyl –CH2–), 3.65 (1H,

J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
2969
J = 6.0, 10.4, 15.2, CH-20); 13C NMR (CDCl3, 100 MHz) d 15.5 (C-18),
15.8 (C-19), 17.6 (C-30), 17.9 (C-6), 21.5 (C-29), 21.8 (Ac, –CH3),
22.2 (C-21), 22.6 (C-2), 24.2 (C-27), 26.0 (C-23), 26.7 (C-16), 27.5
(C-26), 27.8 (C-28), 28.2 (C-11), 31.2 (C-15), 33.9 (C-1), 34.3 (C-
7), 36.7 (C-4), 37.1 (C-10), 38.8 (C-22), 39.7 (C-8), 42.0 (malonyl
–CH2–), 46.2 (C-13), 49.6 (C-9), 50.4 (C-17), 50.6 (C-5), 52.2 (C-
14), 66.0 (C-10), 71.0 (C-25), 75.4 (C-12), 79.7 (C-3), 83.3 (C-24),
85.7 (C-20), 118.9 (C-30), 131.4 (C-20), 165.9 (malonyl –CO–),
166.3 (malonyl –CO–), 170.5 (Ac, –CO–). HRESIMS (positive) m/z
667.4175 [M+Na]+ (calcd for C38H60O8Na, 667.4186).
69.2 (CH-iPr), 71.0 (C-25), 75.4 (C-12), 79.7 (C-3), 83.4 (C-24), 85.8
(C-20), 166.2 (malonyl –CO–), 166.2 (malonyl –CO–), 170.5 (Ac,
–CO–). HRESIMS (positive) m/z 669.4319 [M+Na]+ (calcd for
C38H62O8Na, 669.4342).
4.2.1.12. 3-O-iso-Butylmalonyl-12b-acetoxy-3a,25-dihydroxy-
(20S,24R)-epoxydammarane (16). Yield 40.3% (starting with
50 mg of 1 by method A); colorless oil; ½a D28
ꢂ16.5 (c 0.64, CHCl3).
ꢁ
1H NMR (CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-
19), 0.88 (3H, s, CH3-29), 0.95 (3H, s, CH3-30), 0.95 (6H, d,
J = 7.2 Hz, CH3 ꢀ 2-iBu), 0.99 (3H, s, CH3-18), 1.09 (3H, s, CH3-27),
1.17 (3H, s, CH3-21), 1.18 (3H, s, CH3-26), 1.91–2.00 (1H, m, CH-
iBu), 2.00 (3H, s, CH3-Ac), 3.37 (2H, s, malonyl –CH2–), 3.65 (1H,
dd, J = 6.4, 6.8 Hz, H-24), 3.94 (2H, d, J = 6.4, CH2-iBu), 4.68 (1H,
br s, H-3), 4.83 (1H, dt, J = 5.2, 10.8 Hz, H-12); 13C NMR (CDCl3,
100 MHz) d 15.6 (C-18), 15.8 (C-19), 17.7 (C-30), 18.0 (C-6), 19.0
(CH3 ꢀ 2-iBu), 21.6 (C-29), 21.8 (Ac, –CH3), 22.23 (C-21), 22.7 (C-
2), 24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.6 (C-26), 27.7 (CH-
iBu), 27.9 (C-28), 28.3 (C-11), 31.2 (C-15), 34.0 (C-1), 34.3 (C-7),
36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 42.0 (malonyl
–CH2–), 46.3 (C-13), 49.6 (C-9), 50.5 (C-17), 50.7 (C-5), 52.3
(C-14), 71.0 (C-25), 71.5 (CH2-iBu), 75.5 (C-12), 79.7 (C-3), 83.4
(C-24), 85.7 (C-20), 166.1 (malonyl –CO–), 166.7 (malonyl –CO–),
170.5 (Ac, –CO–). HRESIMS (positive) m/z 683.4502 [M+Na]+ (calcd
for C39H64O8Na, 683.4499).
4.2.1.9. 3-O-tert-Butylmalonyl-12b-acetoxy-3a,25-dihydroxy-
(20S,24R)-epoxydammarane (13). Yield 22.3% (starting with
53 mg of 1 by method A); colorless oil; ½a D28
ꢂ15.6 (c 0.98, CHCl3).
ꢁ
1H NMR (CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.86 (3H, s, CH3-
19), 0.88 (3H, s, CH3-29), 0.95 (3H, s, CH3-30), 0.99 (3H, s, CH3-18),
1.09 (3H, s, CH3-27), 1.17 (3H, s, CH3-21), 1.18 (3H, s, CH3-26), 1.49
(9H, s, CH3 ꢀ 3), 2.00 (3H, s, CH3-Ac), 3.31 (2H, s, malonyl –CH2–),
3.65 (1H, dd, J = 6.8, 7.2 Hz, H-24), 4.67 (1H, br s, H-3), 4.83 (1H, dt,
J = 5.2, 10.8 Hz, H-12); 13C NMR (CDCl3, 100 MHz) d 15.6 (C-18),
15.8 (C-19), 17.7 (C-30), 18.0 (C-6), 21.7 (C-29), 21.8 (Ac, –CH3),
22.3 (C-21), 22.6 (C-2), 24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.5
(C-26), 27.9 (C-28), 28.0 (C ꢀ 3-tBu), 28.3 (C-11), 31.2 (C-15),
34.1 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1 (C-10), 38.9 (C-22), 39.8
(C-8), 43.4 (malonyl –CH2–), 46.3 (C-13), 49.6 (C-9), 50.5 (C-17),
50.6 (C-5), 52.3 (C-14), 71.0 (C-25), 75.5 (C-12), 79.5 (C-3), 83.4
(C-24), 82.0 (C-tBu), 85.7 (C-20), 165.8 (malonyl –CO–), 166.5
(malonyl –CO–), 170.5 (Ac, –CO–). HRESIMS (positive) m/z
683.4490 [M+Na]+ (calcd for C39H64O8Na, 683.4499).
4.2.1.13. 3-O-Ethylmalonyl-3a,25-dihydroxy-(20S,24R)-epox-
ydammarane (17). Yield 23.8% (starting with 49 mg of 2 by meth-
od A); colorless oil; ½a D29
ꢁ
ꢂ3.1(c 1.23, CHCl3). 1H NMR (CDCl3,
400 MHz) d 0.85 (3H, s, CH3-28), 0.85 (3H, s, CH3-19), 0.88 (3H, s,
CH3-29), 0.89 (3H, s, CH3-30), 0.95 (3H, s, CH3-18), 1.11 (3H, s,
CH3-27), 1.12 (3H, s, CH3-21), 1.20 (3H, s, CH3-26), 1.29 (3H, t,
J = 7.2, CH3-Et), 3.39 (2H, s, malonyl –CH2–), 3.72 (1H, t,
J = 7.2 Hz, H-24), 4.21 (2H, q, J = 7.2, CH2-Et), 4.67 (1H, t, J = 2.6,
H-3); 13C NMR (CDCl3, 100 MHz) d 14.2(CH3-Et), 15.5 (C-18), 16.0
(C-19), 16.6 (C-30), 18.1 (C-6), 21.4 (C-11), 21.7 (C-29), 22.8 (C-
2), 23.6 (C-21), 24.3 (C-27), 25.7 (C-16), 26.1 (C-23), 27.4 (C-12),
27.5 (C-26), 27.9 (C-28), 31.5 (C-15), 34.2 (C-1), 35.1 (C-7), 35.7
(C-22), 36.9 (C-4), 37.2 (C-10), 40.6 (C-8), 42.2 (malonyl –CH2–),
42.9 (C-13), 49.5 (C-17), 50.1 (C-14), 50.6 (C-9), 50.8 (C-5), 61.5
(CH2-Et), 71.4 (C-25), 80.0 (C-3), 83.3 (C-24), 86.4 (C-20), 166.1
(malonyl –CO–), 166.8 (malonyl –CO–). HRESIMS (positive) m/z
597.4131 [M+Na]+ (calcd for C35H58O6Na, 597.4131).
4.2.1.10. 3-O-Benzylmalonyl-12b-acetoxy-3a,25-dihydroxy-
(20S,24R)-epoxydammarane (14). Yield 75.0% (starting with
38 mg of 1 by method A); colorless oil; ½a D28
ꢂ10.9 (c 3.36, CHCl3).
ꢁ
1H NMR (CDCl3, 400 MHz) d 0.83 (3H, s, CH3-28), 0.87 (3H, s, CH3-
19), 0.89 (3H, s, CH3-29), 0.95 (3H, s, CH3-30), 1.00 (3H, s, CH3-18),
1.11 (3H, s, CH3-27), 1.19 (3H, s, CH3-21), 1.20 (3H, s, CH3-26), 2.03
(3H, s, CH3-Ac), 3.47 (2H, s, malonyl –CH2–), 3.66 (1H, dd, J = 6.8,
7.6 Hz, H-24), 4.70 (1H, br s, H-3), 4.85 (1H, dt, J = 5.2, 10.4 Hz,
H-12), 5.20 (2H, s, CH2-Benzyl), 7.33-7.39 (5H, m, Ph); 13C NMR
(CDCl3, 100 MHz) d 15.6 (C-18), 15.8 (C-19), 17.7 (C-30), 18.0 (C-
6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.7 (C-2), 24.2 (C-
27), 26.1 (C-23), 26.8 (C-16), 27.6 (C-26), 27.9 (C-28), 28.3 (C-11),
31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1 (C-10), 38.8
(C-22), 39.8 (C-8), 42.0 (malonyl –CH2–), 46.3 (C-13), 49.6 (C-9),
50.5 (C-17), 50.7 (C-5), 52.3 (C-14), 67.2 (CH2-Benzyl), 71.0 (C-
25), 75.5 (C-12), 79.7 (C-3), 83.3 (C-24), 85.7 (C-20), 128.4 (ꢀ2,
C20,60-Ph), 128.6 (ꢀ2, C30,50-Ph), 128.5 (C40-Ph), 135.2 (C10-Ph),
165.9 (malonyl –CO–), 166.5 (malonyl –CO–), 170.5 (Ac, –CO–).
HRESIMS (positive) m/z 717.4333 [M+Na]+ (calcd for C42H64O8Na,
717.4342).
4.2.1.14. 3-O-Propylmalonyl-3a,25-dihydroxy-(20S,24R)-epox-
ydammarane (18). Yield 41.9% (starting with 65 mg of 2 by meth-
od A); colorless oil; ½a D29
ꢁ
ꢂ3.9 (c 2.86, CHCl3). 1H NMR (CDCl3,
400 MHz) d 0.86 (3H, s, CH3-28), 0.86 (3H, s, CH3-19), 0.89 (3H, s,
CH3-29), 0.90 (3H, s, CH3-30), 0.96 (3H, s, CH3-18), 0.96 (3H, t,
J = 6.8, CH3-30), 1.12 (3H, s, CH3-27), 1.13 (3H, s, CH3-21), 1.21
(3H, s, CH3-26), 1.69 (2H, hex, J = 6.8, CH2-20), 3.41 (2H, s, malonyl
–CH2–), 3.73 (1H, t, J = 7.2 Hz, H-24), 4.12 (2H, t, J = 6.8, CH2-10),
4.2.1.11. 3-O-(2-Propyl)malonyl-12b-acetoxy-3a,25-dihydroxy-
(20S,24R)-epoxydammarane (15). Yield 13.6% (starting with
13
4.68 (1H, br s, H-3); C NMR (CDCl3, 100 MHz) d 10.3 (CH3-30),
50 mg of 1 by method B); colorless oil; ½a D28
ꢁ
ꢂ14.1 (c 0.64, CHCl3).
15.4 (C-18), 16.0 (C-19), 16.6 (C-30), 18.0 (C-6), 21.4 (C-11), 21.6
(C-29), 21.8 (C-20), 22.8 (C-2), 23.6 (C-21), 24.3 (C-27), 25.7 (C-
16), 26.1 (C-23), 27.3 (C-12), 27.5 (C-26), 27.9 (C-28), 31.4 (C-15),
34.2 (C-1), 35.1 (C-7), 35.6 (C-22), 36.8 (C-4), 37.1 (C-10), 40.5
(C-8), 42.1 (malonyl –CH2–), 42.8 (C-13), 49.5 (C-17), 50.1 (C-14),
50.6 (C-9), 50.7 (C-5), 67.0 (C-10), 71.4 (C-25), 80.0 (C-3), 83.3 (C-
24), 86.4 (C-20), 166.1 (malonyl –CO–), 166.8 (malonyl –CO–).
HRESIMS (positive) m/z 611.4267 [M+Na]+ (calcd for C36H60O6Na,
611.4288).
1H NMR (CDCl3, 400 MHz) d 0.86 (3H, s, CH3-28), 0.86 (3H, s, CH3-
19), 0.88 (3H, s, CH3-29), 0.96 (3H, s, CH3-30), 0.99 (3H, s, CH3-18),
1.09 (3H, s, CH3-27), 1.17 (3H, s, CH3-21), 1.18 (3H, s, CH3-26), 1.27,
1.28 (each 3H, d, J = 6.4, CH3 ꢀ 2-iPr), 2.00 (3H, s, CH3-Ac), 3.37 (2H,
s, malonyl –CH2–), 3.65 (1H, dd, J = 6.4, 6.8 Hz, H-24), 4.68 (1H, br s,
H-3), 4.83 (1H, dt, J = 5.2, 10.8 Hz, H-12), 5.06 (1H, sept, J = 6.4, CH-
iPr); 13C NMR (CDCl3, 100 MHz) d 15.6 (C-18), 15.9 (C-19), 17.7 (C-
30), 18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 21.8 CH3 ꢀ 2-iPr),
22.23 (C-21), 22.7 (C-2), 24.2 (C-27), 26.1 (C-23), 26.8 (C-16),
27.6 (C-26), 27.9 (C-28), 28.3 (C-11), 31.2 (C-15), 34.0 (C-1), 34.3
(C-7), 36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 42.4 (malonyl
–CH2–), 46.3 (C-13), 49.6 (C-9), 50.5 (C-17), 50.7 (C-5), 52.3 (C-14),
4.2.1.15. 3-O-Butylmalonyl-3a,25-hydroxy-(20S,24R)-epox-
ydammarane (19). Yield 16.9% (starting with 45 mg of 2 by meth-
od A); colorless oil; ½a D30
ꢁ
ꢂ2.6 (c 0.86, CHCl3). 1H NMR (CDCl3,

2970
J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
400 MHz) d 0.86 (3H, s, CH3-28), 0.86 (3H, s, CH3-19), 0.89 (3H, s,
CH3-29), 0.90 (3H, s, CH3-30), 0.96 (3H, s, CH3-18), 1.03 (3H, t,
J = 6.8, CH3-40), 1.12 (3H, s, CH3-27), 1.14 (3H, s, CH3-21), 1.21
(3H, s, CH3-26), 1.37-1.44 (2H, m, CH2-30), 1.61–1.66 (2H, m, CH2-
20), 3.41 (2H, s, malonyl –CH2–), 3.73 (1H, t, J = 7.2 Hz, H-24),
4.16 (2H, t, J = 6.8, CH2-10), 4.68 (1H, br s, H-3); 13C NMR (CDCl3,
100 MHz) d 13.7 (CH3-40), 15.5 (C-18), 16.0 (C-19), 16.6 (C-30),
18.1 (C-6), 19.1 (C-30), 21.4 (C-11), 21.7 (C-29), 22.8 (C-2), 23.6
(C-21), 24.3 (C-27), 25.7 (C-16), 26.1 (C-23), 27.4 (C-12), 27.5 (C-
26), 27.9 (C-28), 30.5 (C-20), 31.5 (C-15), 34.2 (C-1), 35.1 (C-7),
35.6 (C-22), 36.8 (C-4), 37.1 (C-10), 40.5 (C-8), 42.1 (malonyl
–CH2–), 42.9 (C-13), 49.5 (C-17), 50.1 (C-14), 50.6 (C-9), 50.8
(C-5), 65.4 (C-10), 71.4 (C-25), 80.0 (C-3), 83.3 (C-24), 86.4 (C-20),
166.1 (malonyl –CO–), 166.9 (malonyl –CO–). HRESIMS (positive)
m/z 625.4427 [M+Na]+ (calcd for C37H62O6Na, 625.4444).
(C-30), 18.0 (C-6), 21.4 (C-11), 21.6 (C-29), 22.5 (C-60), 22.8 (C-2),
23.6 (C-21), 24.3 (C-27), 25.8 (C-50), 25.7 (C-16), 26.1 (C-23), 27.3
(C-12), 27.5 (C-26), 27.9 (C-28), 28.5 (C-40), 28.9 (C-30), 31.4 (C-
15), 31.7 (C-20), 34.2 (C-1), 35.1 (C-7), 35.6 (C-22), 36.8 (C-4),
37.1 (C-10), 40.5 (C-8), 42.1 (malonyl –CH2–), 42.9 (C-13), 49.5
(C-17), 50.1 (C-14), 50.6 (C-9), 50.7 (C-5), 65.7 (C-10), 71.4 (C-25),
80.0 (C-3), 83.3 (C-24), 86.4 (C-20), 166.1 (malonyl –CO–), 166.8
(malonyl –CO–). HRESIMS (positive) m/z 667.4929 [M+Na]+ (calcd
for C40H68O6Na, 667.4914).
4.2.1.19. 3-O-Oxtylmalonyl-3a,25-dihydroxy-(20S,24R)-epox-
ydammarane (23). Yield 55.4% (starting with 57 mg of 2 by meth-
od A); colorless oil; ½a D30
ꢁ
ꢂ2.3 (c 4.12, CHCl3). 1H NMR (CDCl3,
400 MHz) d 0.85 (3H, s, CH3-28), 0.85 (3H, s, CH3-19), 0.88 (3H, s,
CH3-29), 0.88 (3H, t, J = 6.8, CH3-80), 0.90 (3H, s, CH3-30), 0.96
(3H, s, CH3-18), 1.11 (3H, s, CH3-27), 1.13 (3H, s, CH3-21), 1.20
(3H, s, CH3-26), 1.27 (8H, m, CH2-40, 50, 60, 70), 1.61–1.65 (4H, m,
CH2-20, 30), 3.40 (2H, s, malonyl –CH2–), 3.72 (1H, t, J = 7.2 Hz, H-
24), 4.14 (2H, t, J = 6.8, CH2-10), 4.67 (1H, br s, H-3); 13C NMR
(CDCl3, 100 MHz) d 14.0 (CH3-80), 15.4 (C-18), 16.0 (C-19), 16.6
(C-30), 18.0 (C-6), 21.4 (C-11), 21.6 (C-29), 22.6 (C-70), 22.7 (C-2),
23.5 (C-21), 24.3 (C-27), 25.8 (C-60), 25.7 (C-16), 26.1 (C-23), 27.3
(C-12), 27.4 (C-26), 27.9 (C-28), 28.5 (C-50), 29.1 (C-40), 29.1 (C-
30), 31.4 (C-15), 31.7 (C-20), 34.2 (C-1), 35.1 (C-7), 35.6 (C-22),
36.8 (C-4), 37.1 (C-10), 40.5 (C-8), 42.1 (malonyl –CH2–), 42.8 (C-
13), 49.5 (C-17), 50.1 (C-14), 50.6 (C-9), 50.7 (C-5), 65.6 (C-10),
71.4 (C-25), 79.9 (C-3), 83.3 (C-24), 86.4 (C-20), 166.1 (malonyl
–CO–), 166.8 (malonyl –CO–). HRESIMS (positive) m/z 681.5055
[M+Na]+ (calcd for C41H70O6Na, 681.5070).
4.2.1.16. 3-O-Pentylmalonyl-3a,25-hydroxy-(20S,24R)-epox-
ydammarane (20). Yield 32.0% (starting with 62 mg of 2 by meth-
od A); colorless oil; ½a D30
ꢁ
ꢂ3.0 (c 2.43, CHCl3). 1H NMR (CDCl3,
400 MHz) d 0.86 (3H, s, CH3-28), 0.86 (3H, s, CH3-19), 0.89 (3H, s,
CH3-29), 0.91 (3H, s, CH3-30), 0.91 (3H, t, J = 6.8, CH3-50), 0.96
(3H, s, CH3-18), 1.12 (3H, s, CH3-27), 1.13 (3H, s, CH3-21), 1.21
(3H, s, CH3-26), 1.33 (2H, m, CH2-40), 1.34 (2H, m, CH2-30), 1.66
(2H, m, CH2-20), 3.41 (2H, s, malonyl –CH2–), 3.73 (1H, dd, J = 7.6,
6.8 Hz, H-24), 4.15 (2H, t, J = 6.8, CH2-10), 4.68 (1H, br s, H-3); 13C
NMR (CDCl3, 100 MHz) d 13.9 (CH3-50), 15.4 (C-18), 16.0 (C-19),
16.6 (C-30), 18.0 (C-6), 21.4 (C-11), 21.6 (C-29), 22.3 (C-40), 22.8
(C-2), 23.6 (C-21), 24.3 (C-27), 25.7 (C-16), 26.1 (C-23), 27.3 (C-
12), 27.5 (C-26), 27.9 (C-28), 28.0 (C-30), 28.2 (C-20), 31.4 (C-15),
34.2 (C-1), 35.1 (C-7), 35.6 (C-22), 36.8 (C-4), 37.1 (C-10), 40.6
(C-8), 42.1 (malonyl –CH2–), 42.9 (C-13), 49.5 (C-17), 50.1 (C-14),
50.6 (C-9), 50.7 (C-5), 65.6 (C-10), 71.4 (C-25), 80.0 (C-3), 83.3 (C-
24), 86.4 (C-20), 166.1 (malonyl –CO–), 166.8 (malonyl –CO–).
HRESIMS (positive) m/z 639.4582 [M+Na]+ (calcd for C38H64O6Na,
639.4601).
4.2.1.20. 3-O-(2-Propyl)malonyl-3a,25-dihydroxy-(20S,24R)-
epoxydammarane (24). Yield 23.2% (starting with 60 mg of 2 by
method B); colorless oil; ½a D30
ꢁ
ꢂ4.1 (c 1.43, CHCl3). 1H NMR (CDCl3,
400 MHz) d 0.87 (3H, s, CH3-28), 0.87 (3H, s, CH3-19), 0.90 (3H, s,
CH3-29), 0.90 (3H, s, CH3-30), 0.97 (3H, s, CH3-18), 1.13 (3H, s,
CH3-27), 1.14 (3H, s, CH3-21), 1.22 (3H, s, CH3-26), 1.29 (6H, d,
J = 6.4, 2 ꢀ CH3-iPr), 3.38 (2H, s, malonyl –CH2–), 3.74 (1H, dd,
J = 6.8, 7.2 Hz, H-24), 4.69 (1H, br s, H-3), 5.07 (H, sept, J = 6.4,
CH-iPr); 13C NMR (CDCl3, 100 MHz) d 15.5 (C-18), 16.0 (C-19),
16.6 (C-30), 18.1 (C-6), 21.4 (C-11), 21.7 (C-29), 21.8 (2 ꢀ CH3-
iPr), 22.8 (C-2), 23.6 (C-21), 24.3 (C-27), 25.7 (C-16), 26.1 (C-23),
27.3 (C-12), 27.5 (C-26), 27.9 (C-28), 31.4 (C-15), 34.2 (C-1), 35.0
(C-7), 35.6 (C-22), 36.8 (C-4), 37.1 (C-10), 40.5 (C-8), 42.5 (malonyl
–CH2–), 42.9 (C-13), 49.5 (C-17), 50.1 (C-14), 50.5 (C-9), 50.7 (C-5),
69.1 (CH- iPr), 71.4 (C-25), 79.9 (C-3), 83.3 (C-24), 86.4 (C-20),
166.2 (malonyl –CO–), 166.2 (malonyl –CO–). HRESIMS (positive)
m/z 611.4283 [M+Na]+ (calcd for C36H60O6Na, 611.4288).
4.2.1.17. 3-O-Hexylmalonyl-3a,25-dihydroxy-(20S,24R)-epox-
ydammarane (21). Yield 31.1% (starting with 61 mg of 2 by meth-
od A); colorless oil; ½a D30
ꢁ
ꢂ3.1 (c 2.32, CHCl3). 1H NMR (CDCl3,
400 MHz) d 0.86 (3H, s, CH3-28), 0.86 (3H, s, CH3-19), 0.89 (3H, s,
CH3-29), 0.89 (3H, t, J = 6.8, CH3-60), 0.91 (3H, s, CH3-30), 0.96
(3H, s, CH3-18), 1.12 (3H, s, CH3-27), 1.14 (3H, s, CH3-21), 1.21
(3H, s, CH3-26), 1.29–1.31 (4H, m, CH2-40, 50), 1.62–1.67 (4H, m,
CH2-20, 30), 3.41 (2H, s, malonyl –CH2–), 3.73 (1H, dd, J = 7.6,
6.8 Hz, H-24), 4.15 (2H, t, J = 6.8, CH2-10), 4.68 (1H, br s, H-3); 13C
NMR (CDCl3, 100 MHz) d 14.0 (CH3-60), 15.4 (C-18), 16.0 (C-19),
16.6 (C-30), 18.0 (C-6), 21.4 (C-11), 21.6 (C-29), 22.5 (C-50), 22.8
(C-2), 23.6 (C-21), 24.3 (C-27), 25.5 (C-40), 25.7 (C-16), 26.1 (C-
23), 27.3 (C-12), 27.5 (C-26), 27.9 (C-28), 28.5 (C-30), 31.4 (C-20),
31.4 (C-15), 34.2 (C-1), 35.1 (C-7), 35.6 (C-22), 36.8 (C-4), 37.1
(C-10), 40.6 (C-8), 42.1 (malonyl –CH2–), 42.9 (C-13), 49.5 (C-17),
50.1 (C-14), 50.6 (C-9), 50.7 (C-5), 65.7 (C-10), 71.4 (C-25), 80.0
(C-3), 83.3 (C-24), 86.4 (C-20), 166.1 (malonyl –CO–), 166.8 (malo-
nyl –CO–). HRESIMS (positive) m/z 653.4736 [M+Na]+ (calcd for
C39H66O6Na, 653.4757).
4.2.1.21. 3-O-iso-Butylmalonyl-3a,25-dihydroxy-(20S,24R)-
epoxydammarane (25). Yield 26.6% (starting with 61 mg of 2 by
method B); colorless oil; ½a D30
ꢁ
ꢂ4.7 (c 1.84, CHCl3). 1H NMR (CDCl3,
400 MHz) d 0.86 (3H, s, CH3-28), 0.86 (3H, s, CH3-19), 0.89 (3H, s,
CH3-29), 0.91 (3H, s, CH3-30), 0.95 (6H, d, J = 7.2, 2 ꢀ CH3-iBu),
0.96 (3H, s, CH3-18), 1.13 (3H, s, CH3-27), 1.14 (3H, s, CH3-21),
1.22 (3H, s, CH3-26), 1.97 (1H, m, CH-iBu), 3.42 (2H, s, malonyl
–CH2–), 3.74 (1H, dd, J = 6.8, 7.6 Hz, H-24), 3.95 (H, d, J = 6.4,
CH2-iPr), 4.69 (1H, br s, H-3); 13C NMR (CDCl3, 100 MHz) d 15.5
(C-18), 16.0 (C-19), 16.7 (C-30), 18.1 (C-6), 19.1 (2 ꢀ CH3-iBu),
21.4 (C-11), 21.7 (C-29), 22.8 (C-2), 23.6 (C-21), 24.3 (C-27), 25.7
(C-16), 26.1 (C-23), 27.4 (C-12), 27.5 (C-26), 27.7 (CH-iBu), 27.9
(C-28), 31.5 (C-15), 34.2 (C-1), 35.1 (C-7), 35.6 (C-22), 36.8 (C-4),
37.1 (C-10), 40.6 (C-8), 42.1 (malonyl –CH2–), 42.9 (C-13), 49.5
(C-17), 50.1 (C-14), 50.6 (C-9), 50.8 (C-5), 71.4 (C-25), 71.5
(CH2-iBu), 80.0 (C-3), 83.3 (C-24), 86.4 (C-20), 166.1 (malonyl
–CO–), 166.8 (malonyl –CO–). HRESIMS m/z (positive) 625.4427
[M+Na]+ (calcd for C37H62O6Na, 625.4444).
4.2.1.18. 3-O-Heptylmalonyl-3a,25-dihydroxy-(20S,24R)-epox-
ydammarane (22). Yield 38.7% (starting with 57 mg of 2 by meth-
od A); colorless oil; ½a D30
ꢁ
ꢂ3.8 (c 2.77, CHCl3). 1H NMR (CDCl3,
400 MHz) d 0.86 (3H, s, CH3-28), 0.86 (3H, s, CH3-19), 0.89 (3H, s,
CH3-29), 0.89 (3H, t, J = 6.8, CH3-70), 0.91 (3H, s, CH3-30), 0.96
(3H, s, CH3-18), 1.12 (3H, s, CH3-27), 1.13 (3H, s, CH3-21), 1.21
(3H, s, CH3-26), 1.26–1.32 (6H, m, CH2-40, 50, 60), 1.62–1.67 (4H,
m, CH2-20, 30), 3.41 (2H, s, malonyl –CH2–), 3.73 (1H, t, J = 7.2 Hz,
H-24), 4.15 (2H, t, J = 6.8, CH2-10), 4.68 (1H, br s, H-3); 13C NMR
(CDCl3, 100 MHz) d 14.0 (CH3-70), 15.4 (C-18), 16.0 (C-19), 16.6

J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
2971
4.2.2. General procedure for preparation of amide analogues
(29–38, 39–45)
with 42 mg of 1 by method D); colorless oil; ½a D29
ꢁ
ꢂ14.0 (c 2.10,
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.84 (3H, s, CH3-28), 0.87
(3H, s, CH3-19), 0.90 (3H, s, CH3-29), 0.98 (3H, s, CH3-30), 1.00
(3H, s, CH3-18), 1.11 (3H, s, CH3-27), 1.18 (3H, s, CH3-21), 1.18
(3H, t, J = 7.2 Hz, CH3-Et), 1.19 (3H, s, CH3-26), 2.01 (3H, s, CH3-
Ac), 3.34 (2H, m, N-CH2), 3.35 (2H, s, malonamoyl –CH2–), 3.66
(1H, dd, J = 6.4, 6.8 Hz, H-24), 4.69 (1H, br s, H-3), 4.84 (1H, dt,
J = 5.2, 10.4 Hz, H-12), 7.02 (1H, br s, NH); 13C NMR (CDCl3,
100 MHz) d 14.7 (CH3-Et), 15.6 (C-18), 15.8 (C-19), 17.7 (C-30),
18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.7 (C-2),
24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-26), 27.9 (C-28),
28.2 (C-11), 31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 34.4 (NCH2), 36.8
(C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 41.5 (malonamoyl
–CH2–), 46.2 (C-13), 49.6 (C-9), 50.4 (C-17), 50.6 (C-5), 52.3 (C-
14), 71.0 (C-25), 75.5 (C-12), 79.8 (C-3), 83.3 (C-24), 85.7 (C-20),
164.9 (malonamoyl –CONH), 169.2 (malonamoyl –COO–), 170.5
(Ac, –CO–). HRESIMS (positive) m/z 654.4346 [M+Na]+ (calcd for
C37H61NO7 Na, 654.4346).
Method C: To a solution of 1 (40–60 mg, 1 equiv) in CH2Cl2
(2 mL), oxalyl dichloride (2.0 M solution in CH2Cl2, 3 equiv) was
added dropwise, and the mixture was refluxed for 4 h with stirring.
The reaction mixture was concentrated under reduced pressure to
give a residue. The residue was dissolved in CH2Cl2 (3 mL), and
then an appropriate amine (3 equiv) was added. The mixture was
refluxed for 4 h with stirring. After cooled down to room tempera-
ture, the reaction solution was diluted with CHCl3 and washed by
water, 2 M HCl solution, brine, sat. NaHCO3 solution and brine in
turn. The organic layer was dried over anhydrous Na2SO4 and evap-
orated to give an oily residue. The residue was chromatographed
over a silica gel column and then purified by semi-preparative
HPLC to afford the desired products 29, 31–36, together with com-
pounds 39–45 in each case.
Method D: To a solution of 1 (40–60 mg, 1 equiv), DCC (3 equiv)
and HOBt (3 equiv) in CH2Cl2 (3 mL), excessive amount of an
appropriate amine was added. The reaction mixture was stirred
at room temperature overnight. After filtration of insolubles, the
filtrate was concentrated to dryness, and the residue was subjected
to silica gel chromatography and then repurified by semi-prepara-
tive HPLC to yield the products (26–28, 30, 37, and 38).
4.2.2.4. 3-O-(N-Propyl)malonamoyl-12b-acetoxy-3a,25-dihy-
droxy-(20S,24R)-epoxydammarane (29). Yield 21.7% (starting
with 52 mg of 1 by method C); colorless oil; ½a D28
ꢂ12.7 (c 1.16,
ꢁ
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.84 (3H, s, CH3-28), 0.87
(3H, s, CH3-19), 0.90 (3H, s, CH3-29), 0.94 (3H, t, J = 7.2 Hz,
CH3-30), 0.98 (3H, s, CH3-30), 1.00 (3H, s, CH3-18), 1.11 (3H, s,
CH3-27), 1.18 (3H, s, CH3-21), 1.56 (2H, m, CH2-20), 1.20 (3H, s,
CH3-26), 2.01 (3H, s, CH3-Ac), 3.27(2H, q, J = 6.8 Hz, N-CH2), 3.36
(2H, s, malonamoyl –CH2–), 3.66 (1H, t, J = 7.2 Hz, H-24), 4.69
(1H, br s, H-3), 4.84 (1H, dt, J = 5.2, 10.8 Hz, H-12), 7.08 (1H, br s,
4.2.2.1. 3-O-Malonamoyl-12b-acetoxy-3a,25-dihydroxy-
(20S,24R)-epoxydammarane (26). Yield 30% (starting with 42 mg
of 1 by method D); colorless oil; ½a D29
ꢁ
ꢂ12.7 (c 2.46, CHCl3). 1H
NMR (CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.88 (3H, s,
CH3-19), 0.91 (3H, s, CH3-29), 0.99 (3H, s, CH3-30), 1.00 (3H, s,
CH3-18), 1.11 (3H, s, CH3-27), 1.19 (3H, s, CH3-21), 1.20 (3H, s,
CH3-26), 2.02 (3H, s, CH3-Ac), 3.38 (2H, s, malonamoyl –CH2–),
3.66 (1H, dd, J = 6.8, 7.6 Hz, H-24), 4.71 (1H, br s, H-3), 4.84 (1H,
dt, J = 5.2, 10.4 Hz, H-12), 5.64, 7.09 (each 1H, br s, NH2); 13C
NMR (CDCl3, 100 MHz) d 15.6 (C-18), 15.8 (C-19), 17.8 (C-30),
18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.7 (C-2),
24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-26), 27.9 (C-28),
28.3 (C-11), 31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1
(C-10), 38.8 (C-22), 39.8 (C-8), 41.3 (malonamoyl –CH2–), 46.3
(C-13), 49.5 (C-9), 50.5 (C-17), 50.7 (C-5), 52.3 (C-14), 71.0 (C-
25), 75.5 (C-12), 80.0 (C-3), 83.4 (C-24), 85.7 (C-20), 167.4 (malo-
namoyl –COO–), 168.9 (malonamoyl –CONH2), 170.5 (Ac, –CO–).
HRESIMS (positive) m/z 626.4037 [M+Na]+ (calcd for C35H57NO7
Na, 626.4033).
13
NH); C NMR (CDCl3, 100 MHz) d 11.3 (CH3-30), 15.6 (C-18), 15.8
(C-19), 17.7 (C-30), 18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3
(C-21), 22.6 (C-2), 22.7 (C-20), 24.2 (C-27), 26.1 (C-23), 26.8 (C-
16), 27.5 (C-26), 27.9 (C-28), 28.2 (C-11), 31.2 (C-15), 34.0 (C-1),
34.3 (C-7), 36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 41.3
(NCH2), 41.5 (malonamoyl –CH2–), 46.3 (C-13), 49.6 (C-9), 50.4
(C-17), 50.6 (C-5), 52.3 (C-14), 71.0 (C-25), 75.5 (C-12), 79.8 (C-
3), 83.4 (C-24), 85.7 (C-20), 165.0 (malonamoyl –CONH), 169.3
(malonamoyl –COO–), 170.5 (Ac, –CO–). HRESIMS (positive) m/z
668.4515 [M+Na]+ (calcd for C38H63NO7Na, 668.4502).
4.2.2.5. 3-O-(N-Butyl)malonamoyl-12b-acetoxy-3a,25-dihy-
droxy-(20S,24R)-epoxydammarane (30). Yield 28.1% (starting
with 60 mg of 1 by method D); colorless oil; ½a D17
ꢂ12.7 (c 1.84,
ꢁ
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.84 (3H, s, CH3-28), 0.87
(3H, s, CH3-19), 0.90 (3H, s, CH3-29), 0.93 (3H, t, J = 7.2 Hz,
CH3-40), 0.98 (3H, s, CH3-30), 1.00 (3H, s, CH3-18), 1.11 (3H, s,
CH3-27), 1.18 (3H, s, CH3-21), 1.19 (3H, s, CH3-26), 1.36 (2H, m,
CH2-30), 1.51 (2H, m, CH2-20), 2.01 (3H, s, CH3-Ac), 3.30(2H, q,
J = 6.4 Hz, NCH2), 3.35 (2H, s, malonamoyl –CH2–), 3.66 (1H, dd,
J = 6.4, 8.0 Hz, H-24), 4.69 (1H, br s, H-3), 4.84 (1H, dt, J = 5.2,
10.8 Hz, H-12), 7.07 (1H, br s, NH); 13C NMR (CDCl3, 100 MHz) d
13.7 (CH3-40), 15.6 (C-18), 15.8 (C-19), 17.7 (C-30), 18.0 (C-6),
20.0 (C-30), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.7 (C-2),
24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-26), 27.9 (C-28),
28.2 (C-11), 31.2 (C-15), 31.4 (C-20), 34.0 (C-1), 34.3 (C-7), 36.8
(C-4), 37.1 (C-10), 38.8 (C-22), 39.3 (NCH2), 39.8 (C-8), 41.5 (malo-
namoyl –CH2–), 46.2 (C-13), 49.6 (C-9), 50.4 (C-17), 50.6 (C-5), 52.3
(C-14), 71.0 (C-25), 75.5 (C-12), 79.8 (C-3), 83.3 (C-24), 85.7 (C-20),
164.9 (malonamoyl –CONH), 169.4 (malonamoyl –COO–), 170.5
(Ac, –CO–). HRESIMS (positive) m/z 682.4677 [M+Na]+ (calcd for
C39H65NO7Na, 682.4659).
4.2.2.2. 3-O-(N-Methyl)malonamoyl-12b-acetoxy-3a,25-dihy-
droxy-(20S,24R)-epoxydammarane (27). Yield 46.4% (starting
with 53 mg of 1 by method D); colorless oil; ½a D29
ꢂ14.6 (c 2.97,
ꢁ
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.83 (3H, s, CH3-28), 0.86
(3H, s, CH3-19), 0.89 (3H, s, CH3-29), 0.97 (3H, s, CH3-30), 0.99
(3H, s, CH3-18), 1.09 (3H, s, CH3-27), 1.17 (3H, s, CH3-21), 1.18
(3H, s, CH3-26), 2.00 (3H, s, CH3-Ac), 2.85 (3H, d, J = 4.8 Hz,
NCH3), 3.35 (2H, s, malonamoyl –CH2–), 3.65 (1H, dd, J = 6.4,
7.6 Hz, H-24), 4.67 (1H, br s, H-3), 4.83 (1H, dt, J = 5.2, 10.4 Hz,
H-12), 7.10 (1H, br s, NH); 13C NMR (CDCl3, 100 MHz) d 15.5 (C-
18), 15.8 (C-19), 17.7 (C-30), 17.9 (C-6), 21.6 (C-29), 21.8 (Ac,
–CH3), 22.2 (C-21), 22.6 (C-2), 24.2 (C-27), 26.0 (C-23), 26.3
(NCH3), 26.8 (C-16), 27.5 (C-26), 27.9 (C-28), 28.2 (C-11), 31.2 (C-
15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.0 (C-10), 38.8 (C-22),
39.7 (C-8), 41.3 (malonamoyl –CH2–), 46.2 (C-13), 49.6 (C-9),
50.4 (C-17), 50.6 (C-5), 52.2 (C-14), 71.0 (C-25), 75.5 (C-12), 79.8
(C-3), 83.3 (C-24), 85.7 (C-20), 165.7 (malonamoyl –CONH), 169.2
(malonamoyl –COO–), 170.5 (Ac, –CO–). HRESIMS (positive) m/z
640.4190 [M+Na]+ (calcd for C36H59NO7 Na, 640.4189).
4.2.2.6. 3-O-(N-Pentyl)malonamoyl-12b-acetoxy-3a,25-dihy-
droxy-(20S,24R)-epoxydammarane (31). Yield 26.6% (starting
4.2.2.3. 3-O-(N-Ethyl)malonamoyl-12b-acetoxy-3
droxy-(20S,24R)-epoxydammarane (28). Yield 22.7% (starting
a
,25-dihy-
with 50 mg of 1 by method C); colorless oil; ½a D27
ꢂ12.6 (c 1.43,
ꢁ
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.84 (3H, s, CH3-28), 0.87

2972
J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
(3H, s, CH3-19), 0.90 (3H, s, CH3-29), 0.90 (3H, t, J = 6.8 Hz, CH3-50),
0.98 (3H, s, CH3-30), 1.00 (3H, s, CH3-18), 1.11 (3H, s, CH3-27), 1.18
(3H, s, CH3-21), 1.19 (3H, s, CH3-26), 1.32 (4H, m, CH2-30, 40), 1.58
(2H, m, CH2-20), 2.01 (3H, s, CH3-Ac), 3.29 (2H, q, J = 6.8 Hz, N-
CH2), 3.35 (2H, s, malonamoyl –CH2–), 3.66 (1H, dd, J = 6.4,
8.0 Hz, H-24), 4.69 (1H, br s, H-3), 4.84 (1H, dt, J = 5.2, 10.8 Hz,
H-12), 7.09 (1H, br s, NH); 13C NMR (CDCl3, 100 MHz) d 13.9
(CH3-50), 15.6 (C-18), 15.8 (C-19), 17.7 (C-30), 18.0 (C-6), 21.6 (C-
29), 21.8 (Ac, –CH3), 22.3 (C-40), 22.3 (C-21), 22.7 (C-2), 24.2 (C-
27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-26), 27.9 (C-28), 28.2 (C-11),
29.0 ꢀ 2 (C-20, 30), 31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4),
37.1 (C-10), 38.8 (C-22), 39.6 (NCH2), 39.8 (C-8), 41.5 (malonamoyl
–CH2–), 46.3 (C-13), 49.6 (C-9), 50.4 (C-17), 50.6 (C-5), 52.3 (C-14),
71.0 (C-25), 75.5 (C-12), 79.8 (C-3), 83.3 (C-24), 85.7 (C-20), 164.9
(malonamoyl –CONH), 169.4 (malonamoyl –COO–), 170.5 (Ac,
–CO–). HRESIMS (positive) m/z 696.4822 [M+Na]+ (calcd for
C40H67NO7Na, 696.4815).
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.87 (3H, s, CH3-28), 0.89
(3H, s, CH3-19), 0.92 (3H, s, CH3-29), 0.96 (3H, s, CH3-30), 1.01
(3H, s, CH3-18), 1.12 (3H, s, CH3-27), 1.19 (3H, s, CH3-21), 1.20
(3H, s, CH3-26), 2.02 (3H, s, CH3-Ac), 3.53 (2H, d, J = 2.8 Hz, malona-
moyl –CH2–), 3.66 (1H, dd, J = 6.8, 7.2 Hz, H-24), 4.77 (1H, br s,
H-3), 4.85 (1H, dt, J = 5.2, 10.8 Hz, H-12), 7.13 (1H, t, J = 8 Hz,
–CH–, 40-Ph), 7.34 (2H, t, J = 8 Hz, –CH–, 30,50-Ph), 7.57 (2H, d,
J = 8 Hz, –CH–, 20,60-Ph), 9.16 (1H, br s, NH); 13C NMR (CDCl3,
100 MHz) d 15.6 (C-18), 15.9 (C-19), 17.7 (C-30), 18.0 (C-6), 21.6
(C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.7 (C-2), 24.2 (C-27), 26.1
(C-23), 26.8 (C-16), 27.5 (C-26), 27.9 (C-28), 28.3 (C-11), 31.2 (C-
15), 34.0 (C-1), 34.3 (C-7), 36.9 (C-4), 37.1 (C-10), 38.8 (C-22),
39.8 (C-8), 42.0 (malonamoyl –CH2–), 46.3 (C-13), 49.6 (C-9),
50.5 (C-17), 50.7 (C-5), 52.3 (C-14), 71.0 (C-25), 75.5 (C-12), 80.4
0
0
0
(C-3), 83.4 (C-24), 85.7 (C-20), 120.0 ꢀ 2 (C2 ,6 -Ph), 124.5 (C4 -Ph),
0
0
0
129.0 ꢀ 2 (C3 ,5 -Ph), 137.5 (C1 -Ph), 163.0 (malonamoyl –CONH),
169.5 (malonamoyl –COO–), 170.5 (Ac, –CO–). HRESIMS (positive)
m/z 702.4334 [M+Na]+ (calcd for C41H61NO7Na, 702.4346).
4.2.2.7. 3-O-(N-Nonyl)malonamoyl-12b-acetoxy-3a,25-dihy-
droxy-(20S,24R)-epoxydammarane (32). Yield 20.6% (starting
4.2.2.10. 3-O-(N-2,5-Dimethoxyphenyl)malonamoyl-12b-acet-
with 51 mg of 1 by method C); colorless oil; ½a D27
ꢁ
ꢂ11.2 (c 1.32,
oxy-3
a
,25-dihydroxy-(20S,24R)-epoxydammarane
(35). Yield
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.83 (3H, s, CH3-28), 0.87
(3H, s, CH3-19), 0.87 (3H, t, J = 7.2 Hz, CH3-90), 0.90 (3H, s,
CH3-29), 0.98 (3H, s, CH3-30), 1.00 (3H, s, CH3-18), 1.10 (3H, s,
CH3-27), 1.18 (3H, s, CH3-21), 1.19 (3H, s, CH3-26), 1.26 (12H, m,
CH2-30- CH2-80), 1.55 (2H, m, CH2-20), 2.01 (3H, s, CH3-Ac),
3.27(2H, m, NCH2), 3.35 (2H, s, malonamoyl –CH2–), 3.66 (1H, dd,
J = 6.4, 7.2 Hz, H-24), 4.69 (1H, br s, H-3), 4.84 (1H, dt, J = 5.2,
10.8 Hz, H-12), 7.08 (1H, br s, NH); 13C NMR (CDCl3, 100 MHz) d
14.1 (CH3-90), 15.6 (C-18), 15.8 (C-19), 17.7 (C-30), 18.0 (C-6),
21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.6 (C-80), 22.6 (C-2),
24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 26.9 (C-70), 27.5 (C-26), 27.9
(C-28), 28.2 (C-11), 29.2 ꢀ 2 (C-50, 60), 29.4 (C-40), 29.5 (C-30),
31.2 (C-15), 31.8 (C-20), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1
(C-10), 38.8 (C-22), 39.6 (N-CH2), 39.8 (C-8), 41.5 (malonamoyl
–CH2–), 46.3 (C-13), 49.6 (C-9), 50.4 (C-17), 50.6 (C-5), 52.3 (C-
14), 71.0 (C-25), 75.5 (C-12), 79.8 (C-3), 83.4 (C-24), 85.7 (C-20),
164.9 (malonamoyl –CONH), 169.4 (malonamoyl –COO–), 170.5
(Ac, –CO–). HRESIMS (positive) m/z 752.5468 [M+Na]+ (calcd for
C44H75NO7Na, 752.5441).
16.8% (starting with 50 mg of 1 by method C); colorless oil; ½a D27
ꢁ
ꢂ6.3 (c 1.05, CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.87 (3H, s,
CH3-28), 0.88 (3H, s, CH3-19), 0.91 (3H, s, CH3-29), 0.94 (3H, s,
CH3-30), 1.00 (3H, s, CH3-18), 1.12 (3H, s, CH3-27), 1.19 (3H, s,
CH3-21), 1.20 (3H, s, CH3-26), 2.02 (3H, s, CH3-Ac), 3.53 (2H, d,
J = 2.8 Hz, malonamoyl –CH2–), 3.67 (1H, dd, J = 6.8, 7.2 Hz, H-
24), 3.79 (3H, s, CH3O-50-Ph), 3.88 (3H, s, CH3O-20-Ph), 4.78 (1H,
br s, H-3), 4.84 (1H, dt, J = 5.2, 10.8 Hz, H-12), 6.59 (1H, dd,
J = 2.4, 8.8 Hz, –CH–, 40-Ph), 6.82 (1H, d, J = 8.8 Hz, –CH–, 30-Ph),
8.11 (1H, d, J = 2.8 Hz, –CH–, 60-Ph), 9.39 (1H, br s, NH); 13C NMR
(CDCl3, 100 MHz) d 15.6 (C-18), 15.8 (C-19), 17.7 (C-30), 18.0 (C-
6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.8 (C-2), 24.2 (C-
27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-26), 27.9 (C-28), 28.3 (C-11),
31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 36.9 (C-4), 37.1 (C-10), 38.8
(C-22), 39.8 (C-8), 42.8 (malonamoyl –CH2–), 46.3 (C-13), 49.5
(C-9), 50.5 (C-17), 50.6 (C-5), 52.3 (C-14), 55.8 (CH3O-50-Ph), 56.5
(CH3O-20-Ph), 71.0 (C-25), 75.5 (C-12), 80.0 (C-3), 83.4 (C-24),
0
0
0
85.7 (C-20), 106.39 (C6 -Ph), 108.9 (C3 -Ph), 111.1 (C4 -Ph), 128.1
0
0
0
(C1 -Ph), 142.6 (C2 -Ph), 153.9 (C5 -Ph), 163.0 (malonamoyl –CONH),
168.8 (malonamoyl –COO–), 170.5 (Ac, –CO–). HRESIMS (positive)
m/z 762.4526 [M+Na]+ (calcd for C43H65NO9Na, 762.4557).
4.2.2.8. 3-O-(N-Benzyl)malonamoyl-12b-acetoxy-3a,25-dihy-
droxy-(20S,24R)-epoxydammarane (33). Yield 20.9% (starting
with 38 mg of 1 by method C); colorless oil; ½a D27
ꢁ
ꢂ13.5 (c 1.55,
4.2.2.11. 3-O-(N-tert-Butyl)malonamoyl-12b-acetoxy-3a,25-
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.83 (3H, s, CH3-28), 0.87
(3H, s, CH3-19), 0.89 (3H, s, CH3-29), 0.98 (3H, s, CH3-30), 1.00
(3H, s, CH3-18), 1.11 (3H, s, CH3-27), 1.19 (3H, s, CH3-21), 1.20
(3H, s, CH3-26), 2.02 (3H, s, CH3-Ac), 3.42 (2H, s, malonamoyl
–CH2–), 3.66 (1H, dd, J = 6, 6.8 Hz, H-24), 4.49, 4.50 (each d,
J = 5.6 Hz, NCH2), 4.69 (1H, br s, H-3), 4.85 (1H, dt, J = 5.2,
10.8 Hz, H-12), 7.29–7.36 (5H, m, Ph), 7.42 (1H, br s, NH); 13C
NMR (CDCl3, 100 MHz) d 15.6 (C-18), 15.8 (C-19), 17.7 (C-30),
18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.7 (C-2),
24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-26), 27.9 (C-28),
28.2 (C-11), 31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1
(C-10), 38.8 (C-22), 39.8 (C-8), 41.4 (malonamoyl –CH2–), 43.6
(NCH2), 46.3 (C-13), 49.6 (C-9), 50.4 (C-17), 50.6 (C-5), 52.3 (C-
14), 71.0 (C-25), 75.5 (C-12), 79.9 (C-3), 83.3 (C-24), 85.7 (C-20),
dihydroxy-(20S,24R)-epoxydammarane (36). Yield 11.9% (start-
ing with 40 mg of 1 by method C); colorless oil; ½a D27
ꢂ13.1 (c 1.52,
ꢁ
CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.85 (3H, s, CH3-28), 0.87 (3H,
s, CH3-19), 0.90 (3H, s, CH3-29), 0.99 (3H, s, CH3-30), 1.00 (3H, s,
CH3-18), 1.11 (3H, s, CH3-27), 1.18 (3H, s, CH3-21), 1.20 (3H, s,
CH3-26), 1.38 (9H, s, CH3 ꢀ 3-tert-butyl), 2.00 (3H, s, CH3-Ac), 3.27
(2H, d, J = 2.8 Hz, malonamoyl –CH2–), 3.66 (1H, dd, J = 6.4, 6.8 Hz,
H-24), 4.69 (1H, br s, H-3), 4.84 (1H, dt, J = 5.2, 10.8 Hz, H-12), 6.79
(1H, br s, NH); 13C NMR (CDCl3, 100 MHz) d 15.6 (C-18), 15.8
(C-19), 17.8 (C-30), 18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3
(C-21), 22.7 (C-2), 24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-
26), 27.9 (C-28), 28.2 (C-11), 28.7 ꢀ 3 (CH3-tert-butyl), 31.2 (C-15),
34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-
8), 42.8 (malonamoyl –CH2–), 46.2 (C-13), 49.6 (C-9), 50.4 (C-17),
50.6 (C-5), 51.3 (NHC), 52.3 (C-14), 71.0 (C-25), 75.5 (C-12), 79.7
(C-3), 83.3 (C-24), 85.7 (C-20), 164.1 (malonamoyl –CONH), 169.5
(malonamoyl –COO–), 170.5 (Ac, –CO–). HRESIMS (positive) m/z
682.4658 [M+Na]+ (calcd for C39H65NO7Na, 682.4569).
0
0
0
0
0
127.5 (C4 -Ph), 127.7 ꢀ 2 (C2 ,6 -Ph), 128.7 ꢀ 2 (C3 ,5 -Ph), 137.9
0
(C1 -Ph),165.0 (malonamoyl –CONH), 169.2 (malonamoyl –COO–),
170.5 (Ac, –CO–). HRESIMS (positive) m/z 716.4473 [M+Na]+ (calcd
for C42H63NO7Na, 716.4502).
4.2.2.9. 3-O-(N-Phenyl)malonamoyl-12b-acetoxy-3
a
,25-dihy-
4.2.2.12. 3-O-(Morpholino-b-oxopropanoyl)-12b-acetoxy-
droxy-(20S,24R)-epoxydammarane (34). Yield 25.8% (starting
3a,25-dihydroxy-(20S,24R)-epoxydammarane (37). Yield 85.8%
with 38 mg of 1 by method C); colorless oil; ½a D27
ꢁ
ꢂ8.2 (c 1.29,
(starting with 43 mg of 1 by method D); colorless oil; ½a D27
ꢂ12.3
ꢁ

J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
2973
(c 4.60, CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.84 (3H, s, CH3-28),
0.85 (3H, s, CH3-19), 0.87 (3H, s, CH3-29), 0.96 (3H, s, CH3-30),
0.98 (3H, s, CH3-18), 1.08 (3H, s, CH3-27), 1.16 (3H, s, CH3-21),
1.17 (3H, s, CH3-26), 2.00 (3H, s, CH3-Ac), 3.43-3.49 (2H, m, CH2-
mor), 3.49 (2H, s, b-oxopropanoyl –CH2–), 3.58-3.64 (2H, m, CH2-
mor), 3.66 (1H, t, J = 6.8 Hz, H-24), 3.68–3.71 (4H, m, CH2-mor),
4.67 (1H, br s, H-3), 4.82 (1H, dt, J = 5.2, 10.8 Hz, H-12); 13C NMR
(CDCl3, 100 MHz) d 15.5 (C-18), 15.8 (C-19), 17.7 (C-30), 17.9 (C-
6), 21.5 (C-29), 21.8 (Ac, –CH3), 22.2 (C-21), 22.7 (C-2), 24.1 (C-
27), 26.0 (C-23), 26.7 (C-16), 27.5 (C-26), 27.9 (C-28), 28.2 (C-11),
31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 35.5, 36.7 (C-4), 37.0 (C-10),
38.7 (C-22), 39.7 (C-8), 41.2 (b-oxopropanoyl –CH2–), 42.2 (CH2-
mor), 46.2 (C-13), 46.8 (CH2-mor), 49.6 (C-9), 50.4 (C-17), 50.6
(C-5), 52.2 (C-14), 66.4 (CH2-mor), 66.7 (CH2-mor), 70.9 (C-25),
75.4 (C-12), 79.9 (C-3), 83.3 (C-24), 85.7 (C-20), 164.6 (b-oxoprop-
anoyl, –CONH), 167.0 (b-oxopropanoyl –COO–), 170.5 (Ac, –CO–).
HRESIMS (positive) m/z 696.4438 [M+Na]+ (calcd for C39H63NO8
Na, 696.4451).
(3H, s, CH3-28), 0.87 (3H, s, CH3-19), 0.89 (3H, s, CH3-29), 0.89
(6H, m, CH3-50, CH3-500), 0.97 (3H, s, CH3-30), 0.99 (3H, s, CH3-
18), 1.17 (3H, s, CH3-21), 1.32 (8H, m, CH2-30, 40, CH2-300, 400), 1.50
(6H, s, CH3-26, 27), 1.54 (4H, m, CH2-20, CH2-200), 2.00 (3H, s,
CH3-Ac), 3.29 (4H, q, J = 6.8 Hz, CH2-10, CH2-100), 3.35 (2H, s, malo-
namoyl –CH2–), 4.03 (1H, t, J = 7.2 Hz, H-24), 4.69 (1H, br s, H-3),
4.84 (1H, dt, J = 5.2, 10.8 Hz, H-12), 7.01 (1H, br s, oxamoyl -NH),
13
7.10 (1H, br s, NH); C NMR (CDCl3, 100 MHz) d 13.9 (CH3-500),
13.9 (CH3-50), 15.6 (C-18), 15.8 (C-19), 17.5 (C-30), 18.0 (C-6),
21.1 (C-27), 21.5 (C-21), 21.6 (C-29), 21.8 (Ac, –CH3), 22.2 (CH2-
400), 22.3 (C-26), 22.3 (C-40), 22.7 (C-2), 25.9 (C-23), 27.2 (C-16),
27.9 (C-28), 28.2 (C-11), 28.8 (CH2-300), 28.9 (CH2-200), 29.0 ꢀ 2
(C-20, 30), 31.0 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1 (C-
10), 38.9 (C-22), 39.6 (C-10), 39.8 (C-8), 39.7 (CH2-100), 41.4 (malo-
namoyl –CH2–), 46.2 (C-13), 49.5 (C-9), 50.6 (C-17), 50.6 (C-5), 52.3
(C-14), 75.6 (C-12), 79.8 (C-3), 81.4 (C-24), 86.4 (C-20), 86.9 (C-25),
157.2 (oxamoyl, –CONH), 159.7 (oxamoyl, –COO–), 164.9 (malona-
moyl –CONH), 169.4 (malonamoyl –COO-), 170.4 (Ac, –CO–). HRE-
SIMS (positive) m/z 837.5610 [M+Na]+ (calcd for C47H78N2O9Na,
837.5605).
4.2.2.13. 3-O-(N-Dimethyl)malonamoyl-12b-acetoxy-3a,25-
dihydroxy-(20S,24R)-epoxydammarane (38). Yield 45.4% (start-
ing with 42 mg of 1 by method D); colorless oil; ½a D27
ꢁ
ꢂ14.7 (c
4.2.2.16. 3-O-(N-Nonyl)malonamoyl-12b-acetoxy-25-O-(N-
nonyl)oxamoyl-3a,25-dihydroxy-(20S,24R)-epoxydammarane
2.92, CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.83 (3H, s, CH3-28),
0.87 (3H, s, CH3-19), 0.89 (3H, s, CH3-29), 0.98 (3H, s, CH3-30),
1.00 (3H, s, CH3-18), 1.10 (3H, s, CH3-27), 1.18 (3H, s, CH3-21),
1.20 (3H, s, CH3-26), 2.02 (3H, s, CH3-Ac), 3.01, 3.06 (each 3H, s,
(CH3)2N), 3.50 (2H, s, malonamoyl –CH2–), 3.65 (1H, dd, J = 6.8,
7.2 Hz, H-24), 4.69 (1H, br s, H-3), 4.84 (1H, dt, J = 5.2, 10.4 Hz,
H-12); 13C NMR (CDCl3, 100 MHz) d 15.5(C-18), 15.9 (C-19), 17.7
(C-30), 18.0 (C-6), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-21), 22.7
(C-2), 24.2 (C-27), 26.1 (C-23), 26.8 (C-16), 27.5 (C-26), 27.9 (C-
28), 28.2 (C-11), 31.2 (C-15), 34.0 (C-1), 34.3 (C-7), 35.5, 38.0
((CH3)2N), 36.8 (C-4), 37.1 (C-10), 38.8 (C-22), 39.8 (C-8), 41.7
(malonamoyl –CH2–), 46.2 (C-13), 49.7 (C-9), 50.4 (C-17), 50.7
(C-5), 52.3 (C-14), 71.0 (C-25), 75.5 (C-12), 79.5 (C-3), 83.3 (C-
24), 85.7 (C-20), 166.1 (malonamoyl –CONH), 167.2 (malonamoyl
–COO–), 170.6 (Ac, –CO–). HRESIMS (positive) m/z 654.4343
[M+Na]+ (calcd for C37H61NO7Na, 654.4346).
(41). Yield 25.8% (starting with 51 mg of 1 by method C); colorless
oil; ½a 2D7
ꢁ
ꢂ9.4 (c 1.12, CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.84 (3H,
s, CH3-28), 0.87 (3H, s, CH3-19), 0.87 (6H, t, J = 7.2 Hz, CH3-90,
oxamyl, –CH3), 0.90 (3H, s, CH3-29), 0.98 (3H, s, CH3-30), 0.99
(3H, s, CH3-18), 1.17 (3H, s, CH3-21), 1.27 (24H, m, CH2-30- CH2-
80, CH2-300-CH2-800), 1.51 (6H, s, CH3-26, 27), 1.54 (4H, m, CH2-20,
CH2-200), 2.00 (3H, s, CH3-Ac), 3.29 (4H, q, J = 6.8 Hz, CH2-10, CH2-
100), 3.36 (2H, s, malonamoyl –CH2–), 4.04 (1H, t, J = 7.2 Hz, H-24),
4.69 (1H, br s, H-3), 4.85 (1H, dt, J = 5.2, 10.8 Hz, H-12), 7.00 (1H,
br s, oxamoyl-NH), 7.09 (1H, br s, NH); 13C NMR (CDCl3,
100 MHz) d 14.1 ꢀ 2 (CH3-900, CH3-90), 15.6 (C-18), 15.8 (C-19),
17.5 (C-30), 18.0 (C-6), 21.1 (C-27), 21.5 (C-21), 21.6 (C-29), 21.8
(Ac, –CH3), 22.2 (C-26), 22.6 ꢀ 3 (C-2, C-80, C-800), 25.9 (C-23),
26.8 (C-700), 26.9 (C-70), 27.2 (C-16), 27.9 (C-28), 28.2 (C-11),
29.2 ꢀ 4 (C-50, 60, C-500, 600), 29.2 (C-400), 29.4 (C-40), 29.4 ꢀ 2 (C-30,
C-300), 31.8 ꢀ 3 (C-15, C-20, C-200), 34.0 (C-1), 34.3 (C-7), 36.8 (C-
4), 37.1 (C-10), 38.9 (C-22), 39.6 (C-10), 39.8 (C-8), 39.7 (C-100),
41.4 (malonamoyl –CH2–), 46.2 (C-13), 49.5 (C-9), 50.6 (C-17),
50.6 (C-5), 52.3 (C-14), 75.6 (C-12), 79.8 (C-3), 81.3 (C-24), 86.4
(C-20), 86.9 (C-25), 157.2 (oxamoyl, –CONH), 159.7 (oxamoyl,
–COO–), 164.9 (malonamoyl –CONH), 169.4 (malonamoyl –COO–),
170.4 (Ac, –CO–). HRESIMS (negative) m/z 971.6942 [M+HCOO]ꢂ
(calcd for C56H95N2O11, 971.6936).
4.2.2.14. 3-O-(N-Propyl)malonamoyl-12b-acetoxy-25-O-(N-pro-
pyl)oxamoyl-3a,25-dihydroxy-(20S,24R)-epoxydammarane
(39). Yield 19.0% (starting with 41 mg of 1 by method C); colorless
oil; ½a 2D7
ꢁ
ꢂ20.6 (c 0.98, CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.84
(3H, s, CH3-28), 0.87 (3H, s, CH3-19), 0.90 (3H, s, CH3-29), 0.94
(3H, t, J = 7.2 Hz, CH3-30), 0.95 (3H, t, J = 7.2 Hz, CH3-300), 0.98 (3H,
s, CH3-30), 0.99 (3H, s, CH3-18), 1.17 (3H, s, CH3-21), 1.51 (6H, s,
CH3-27, 26), 1.57 (4H, m, CH2-20, CH2-200), 2.00 (3H, s, CH3-Ac),
3.28 (4H, q, J = 6.8 Hz, CH2-10, CH2-100), 3.36 (2H, s, malonamoyl
–CH2–), 4.02 (1H, t, J = 7.2 Hz, H-24), 4.69 (1H, br s, H-3), 4.84 (1H,
dt, J = 5.2, 10.8 Hz, H-12), 7.02 (1H, br s, oxamoyl -NH), 7.09 (1H,
4.2.2.17. 3-O-(N-Benzyl)malonamoyl-12b-acetoxy-25-O-(N-
benzyl)oxamoyl-3a,25-dihydroxy-(20S,24R)-epoxydammarane
(42). Yield 9.5% (starting with 38 mg of 1 by method C); colorless
br s, -NH); C NMR (CDCl3, 100 MHz) d 11.3 (CH3-300), 11.4 (CH3-
oil; ½a 2D7
ꢁ
ꢂ19.1 (c 1.06, CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.83
13
30), 15.6 (C-18), 15.8 (C-19), 17.5 (C-30), 18.0 (C-6), 21.1 (C-27),
21.5 (C-21), 21.6 (C-29), 21.8 (Ac, –CH3), 22.3 (C-26), 22.5 (C-200),
22.6 (C-2), 22.6 (C-20), 25.9 (C-23), 27.2 (C-16), 27.9 (C-28), 28.2
(C-11), 31.0 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1 (C-10),
38.9 (C-22), 39.7 (C-8), 41.3 (C-10), 41.5 (C-100),41.5 (malonamoyl
–CH2–), 46.2 (C-13), 49.5 (C-9), 50.6 (C-17), 50.6 (C-5), 52.3 (C-14),
75.6 (C-12), 79.9 (C-3), 81.4 (C-24), 86.4 (C-20), 86.9 (C-25), 157.2
(oxamoyl, –CONH), 159.7 (oxamoyl, –COO–), 165.0 (malonamoyl
–CONH), 169.4 (malonamoyl –COO–), 170.5 (Ac, –CO–). HRESIMS
(positive) m/z 781.4949 [M+Na]+ (calcd for C43H70N2O9Na, 781.4979).
(3H, s, CH3-28), 0.87 (3H, s, CH3-19), 0.90 (3H, s, CH3-29), 0.96
(3H, s, CH3-30), 0.99 (3H, s, CH3-18), 1.17 (3H, s, CH3-21), 1.52
(6H, s, CH3-27, 26), 2.01 (3H, s, CH3-Ac), 3.42 (2H, s, malonamoyl
–CH2–), 4.03 (1H, t, J = 7.2 Hz, H-24), 4.49(2H, d, J = 6.0 Hz, oxa-
moyl-NCH2), 4.49, 4.50 (2H, each d, J = 6.4 Hz, NCH2), 4.69 (1H, br
s, H-3), 4.85 (1H, dt, J = 5.2, 10.8 Hz, H-12), 7.28-7.34 (10H, m,
Ph, oxamoyl-Ph), 7.35 (1H, br s, oxamoyl-NH), 7.36 (1H, br s,
NH); 13C NMR (CDCl3, 100 MHz) d 15.6 (C-18), 15.8 (C-19), 17.5
(C-30), 18.0 (C-6), 21.2 (C-27), 21.5 (C-21), 21.6 (C-29), 21.8 (Ac,
–CH3), 22.1 (C-26), 22.7 (C-2), 25.9 (C-23), 27.2 (C-16), 27.9 (C-
28), 28.2 (C-11), 31.0 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4),
37.1 (C-10), 38.9 (C-22), 39.7 (C-8), 41.4 (malonamoyl –CH2–),
43.6 (NCH2), 43.9 (oxamoyl-NCH2), 46.2 (C-13), 49.5 (C-9), 50.6
(C-17), 50.6 (C-5), 52.3 (C-14), 75.6 (C-12), 80.0 (C-3), 81.4 (C-
4.2.2.15. 3-O-(N-Pentyl)malonamoyl-12b-acetoxy-25-O-(N-pen-
tyl)oxamoyl-3a,25-dihydroxy-(20S,24R)-epoxydammarane
(40). Yield 23.4% (starting with 51 mg of 1 by method C); colorless
oil; ½a 2D7
ꢁ
ꢂ19.3 (c 2.18, CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.83
24), 86.4 (C-20), 87.2 (C-25), 127.5 (C4 -Ph), 127.7 ꢀ 2 (C2 ,6 -Ph),
0
0
0

2974
J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
0
0
0
127.8 (oxamoyl-C4 -Ph), 128.0 ꢀ 2 (oxamoyl-C2 ,6 -Ph), 128.7 ꢀ 2
4.2.2.20. 3-O-(N-tert-Butyl)malonamoyl-12b-acetoxy-25-O-(N-
tert-butyl)oxamoyl-3 ,25-dihydroxy-(20S,24R)-epoxydamma-
0
0
0
0
0
(C3 ,5 -Ph), 137.0 ꢀ 2 (oxamoyl-C3 ,5 -Ph), 137.0 (oxamoyl-C1 -Ph),
a
0
137.9 (C1 -Ph), 157.2 (oxamoyl –CONH), 159.5 (oxamoyl –COO–),
rane (45). Yield 22.1% (starting with 40 mg of 1 by method C); col-
165.0 (malonamoyl –CONH), 169.2 (malonamoyl –COO–), 170.5
(Ac, –CO–). HRESIMS (positive) m/z 877.4991 [M+Na]+ (C51H70N2O9Na,
877.4979).
orless oil; ½a 2D7
ꢁ
ꢂ19.6 (c 1.05, CHCl3). 1H NMR (CDCl3, 400 MHz) d
0.84 (3H, s, CH3-28), 0.87 (3H, s, CH3-19), 0.90 (3H, s, CH3-29),
0.98 (3H, s, CH3-30), 0.99 (3H, s, CH3-18), 1.18 (3H, s, CH3-21),
1.50 (6H, s, CH3-26, 27), 1.38 (18H, s, CH3 ꢀ 3-tBu, oxamoyl
CH3 ꢀ 3-tBu), 2.02 (3H, s, CH3-Ac), 3.28 (2H,d, J = 3.6 Hz, malona-
moyl –CH2–), 4.00 (1H, t, J = 7.2 Hz, H-24), 4.68 (1H, br s, H-3),
4.84 (1H, dt, J = 5.2, 10.8 Hz, H-12), 6.80 (1H, br s, NH), 6.92 (1H,
br s, oxamoyl-NH); 13C NMR (CDCl3, 100 MHz) d 15.6 (C-18), 15.8
(C-19), 17.5 (C-30), 18.0 (C-6), 21.0 (C-27), 21.6 (C-21), 21.6 (C-
29), 21.8 (Ac, –CH3), 22.1 (C-26), 22.7 (C-2), 25.9 (C-23), 27.2 (C-
16), 27.9 (C-28), 28.2 (C-11), 28.2 ꢀ 3 (oxamoyl CH3-tBu),
28.7 ꢀ 3 (CH3-tBu), 31.0 (C-15), 34.0 (C-1), 34.3 (C-7), 36.8 (C-4),
37.1 (C-10), 38.9 (C-22), 39.7 (C-8), 42.8 (malonamoyl –CH2–),
46.2 (C-13), 49.4 (C-9), 50.6 ꢀ 2 (C-17, C-5), 51.3 (C-tBu), 51.6 (oxa-
moyl C-tBu), 52.3 (C-14), 75.6 (C-12), 79.8 (C-3), 81.7 (C-24), 86.5
(C-20), 86.7 (C-25), 156.2 (oxamoyl, –CONH), 160.3 (oxamoyl
–COO–), 164.1 (malonamoyl –CONH), 169.5 (malonamoyl –COO–),
170.5 (Ac, –CO–). HRESIMS (negative) m/z 831.5391 [M+HCOO]ꢂ
(calcd for C46H75N2O11, 831.5371).
4.2.2.18. 3-O-(N-Phenyl)malonamoyl-12b-acetoxy-25-O-(N-
phenyl)oxamoyl-3a,25-dihydroxy-(20S,24R)-epoxydammarane
(43). Yield 3.9% (starting with 38 mg of 1 by method C); colorless
oil; ½a 2D7
ꢁ
ꢂ17.6 (c 1.08, CHCl3). 1H NMR (CDCl3, 400 MHz) d 0.87
(3H, s, CH3-28), 0.89 (3H, s, CH3-19), 0.92 (3H, s, CH3-29), 0.97
(3H, s, CH3-30), 1.00 (3H, s, CH3-18), 1.20 (3H, s, CH3-21), 1.56
(6H, s, CH3-27, 26), 2.02 (3H, s, CH3-Ac), 3.54 (2H, d, J = 2.8 Hz,
malonamoyl –CH2–), 4.05 (1H, t, J = 7.2 Hz, H-24), 4.77 (1H, br s,
H-3), 4.87 (1H, dt, J = 5.2, 10.8 Hz, H-12), 7.13 (1H, t, J = 8 Hz,
–CH–, 40-Ph), 7.18 (1H, t, J = 8 Hz, –CH–, oxamoyl-Ph-40), 7.34
(2H, t, J = 8 Hz, –CH–, 30,50-Ph), 7.38 (2H, t, J = 8 Hz, –CH–, oxa-
moyl-Ph-30,50), 7.57 (2H, d, J = 8 Hz, –CH–, 20,60-Ph), 7.63 (2H, d,
J = 8 Hz, –CH–, oxamoyl-Ph-20,60), 8.84 (1H, br s, oxamoyl-NH),
9.19 (1H, br s, NH); 13C NMR (CDCl3, 100 MHz) d 15.6 (C-18),
15.8 (C-19), 17.5 (C-30), 18.0 (C-6), 21.3 (C-27), 21.6 ꢀ 2 (C-21,
29), 21.8 (Ac, –CH3), 22.1 (C-26), 22.8 (C-2), 25.9 (C-23), 27.2 (C-
16), 28.0 (C-28), 28.2 (C-11), 31.1 (C-15), 34.0 (C-1), 34.3 (C-7),
36.9 (C-4), 37.1 (C-10), 38.9 (C-22), 39.8 (C-8), 41.9 (malonamoyl
–CH2–), 46.2 (C-13), 49.5 (C-9), 50.6 (C-17), 50.7 (C-5), 52.3 (C-
14), 75.6 (C-12), 80.4 (C-3), 81.7 (C-24), 86.5 (C-20), 87.5 (C-25),
4.3. Biological activity
4.3.1. Cell lines and cell culture
KB cell line (human epidermoid carcinoma of the nasopharynx)
was obtained from the Cell Resource Center for Biomedical Re-
search (Tohoku University). Multidrug-resistant human epider-
moid carcinoma KB-C2 cells were kindly provided by Professor
Shin-ichi Akiyama (Kagoshima University, Japan). KB cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS). KB-C2 cells were main-
0
0
0
0
0
119.6 ꢀ 2 (oxamoyl-C2 ,6 -Ph), 120.7 ꢀ 2 (C2 ,6 -Ph), 124.5 (C4 -Ph),
0
0
0
125.2 (oxamoyl-C4 -Ph), 129.0 ꢀ 2 (C3 ,5 -Ph), 129.2 ꢀ 2 (oxa-
0
0
0
0
moyl-C3 ,5 -Ph), 136.6 (oxamoyl-C1 -Ph), 137.5 (C1 -Ph), 154.5 (oxa-
moyl, –CONH), 159.8 (oxamoyl –COO–), 163.0 (malonamoyl
–CONH), 169.5 (malonamoyl –COO–), 170.5 (Ac, –CO–). HRESIMS
(negative) m/z 871.4780 [M+HCOO]ꢂ (calcd for C50H67N2O11Na,
871.4745).
tained in DEME medium in the presence of 10% FBS and 2 lg/mL
colchicine. All cells were incubated at 37 °C in a humidified atmo-
sphere with 5% CO2–95% air.
4.2.2.19. 3-O-(N-2,5-Dimethoxyphenyl)malonamoyl-12b-acet-
oxy-25-O-(N-2,5-dimethoxyphenyl)oxamoyl-3a,25-dihydroxy-
4.3.2. Assay for cytotoxicity effect
(20S,24R)-epoxydammarane (44). Yield 25.3% (starting with
Cells in exponential growth were trypsinized, dispersed in a sin-
51 mg of 1 by method C); colorless oil; ½a D27
ꢂ11.5 (c 1.86, CHCl3).
ꢁ
gle cell suspension, and dispensed in 100 lL volumes into 96-well
1H NMR (CDCl3, 400 MHz) d 0.86 (3H, s, CH3-28), 0.87 (3H, s, CH3-
19), 0.91 (3H, s, CH3-29), 0.94 (3H, s, CH3-30), 0.99 (3H, s, CH3-18),
1.19 (3H, s, CH3-21), 1.57 (6H, s, CH3-26, 27), 2.02 (3H, s, CH3-Ac),
3.54 (2H, d, J = 2.8 Hz, malonamoyl –CH2–), 3.78 (3H, s, oxamoyl
CH3O-50-Ph), 3.80 (3H, s, CH3O-50-Ph), 3.87 (3H, s, CH3O-20-Ph),
3.87 (3H, s, oxamoyl CH3O-20-Ph), 4.05 (1H, t, J = 7.2 Hz, H-24),
4.77 (1H, br s, H-3), 4.87 (1H, dt, J = 5.2, 10.8 Hz, H-12), 6.59 (1H,
dd, J = 2.8, 8.8 Hz, –CH–, 40-Ph), 6.66 (1H, dd, J = 2.8, 8.8 Hz, –CH–,
oxamoyl 40-Ph), 6.82 (1H, d, J = 8.8 Hz, –CH–, 30-Ph), 6.83 (1H, d,
J = 8.8 Hz, –CH–, oxamoyl 30-Ph), 8.11 (1H, d, J = 2.8 Hz, –CH–, 60-
Ph), 8.15 (1H, d, J = 2.8 Hz, –CH–, oxamoyl 60-Ph), 9.43 (1H, br s,
NH), 9.47 (1H, br s, oxamoyl-NH); 13C NMR (CDCl3, 100 MHz) d
15.5 (C-18), 15.8 (C-19), 17.4 (C-30), 18.0 (C-6), 21.1 (C-27),
21.6 ꢀ 2 (C-21, C-29), 21.8 (Ac, –CH3), 22.4 (C-26), 22.8 (C-2),
25.9 (C-23), 27.2 (C-16), 27.9 (C-28), 28.2 (C-11), 31.0 (C-15),
34.0 (C-1), 34.3 (C-7), 36.8 (C-4), 37.1 (C-10), 38.9 (C-22), 39.7
(C-8), 42.7 (malonamoyl –CH2–), 46.2 (C-13), 49.4 (C-9), 50.5 (C-
17), 50.6 (C-5), 52.2 (C-14), 75.6 (C-12), 80.0 (C-3), 81.6 (C-24),
plates. For each assay, 5 ꢀ 103 cells/well were inoculated in 100
lL
of medium containing 10% FBS and incubated for 24 h. Test sam-
ples were dissolved in small amounts of DMSO and diluted in
appropriate culture medium (0.5% DMSO final concentration).
After removal of preincubated culture medium, 100
containing various concentrations (2, 10, 50, 100
test compound was added, and the plates were further incubated
for 48 h. Followed by removal of the mixture, 100 L of fresh med-
lL of medium
lg/mL) of each
l
ium containing 0.5 mg/mL MTT (thiazoil blue) was added to each
well.24,25 After incubation at 37 °C for another 4 h, medium was
discarded carefully and 100 lL DMSO was added to dissolve the
purple formazan. The cell growth was determined by measuring
the optical density (OD) at 540 nm with Sunrise microplate reader
(Tecan, Switzerland). IC50 values are defined as the concentration
of each test sample that reduced absorbance to 50% of vehicle-trea-
ted controls. Daunorubicin was used as a positive control.
4.3.3. Assay for MDR-reversing activity in KB-C2 cells
Cells were seeded at a density of 5 ꢀ 103 per well in 96-well
0
0
86.5 (C-20), 87.3 (C-25), 105.6 (oxamyl C6 -Ph), 106.4 (C6 -Ph),
0
0
0
108.9 (C3 -Ph), 110.2 (oxamoyl C3 -Ph), 110.9 (oxamoyl C4 -Ph),
plates and incubated for 24 h. After preincubated medium was re-
0
0
0
111.0 (C4 -Ph), 126.9 (oxamoyl C1 -Ph), 128.1 (C1 -Ph), 142.5 (oxa-
moved, 100
lL of medium containing various concentration of col-
0
0
0
0
moyl C2 -Ph), 142.6 (C2 -Ph), 153.8 ꢀ 2 (C5 -Ph, oxamoyl C5 -Ph),
154.3 (oxamoyl, –CONH), 159.2 (oxamoyl –COO–), 163.0 (malona-
moyl –CONH), 168.9 (malonamoyl –COO–), 170.4 (Ac, –CO–). HRE-
chicine in the presence of each test sample (1 or 5
lg/mL) was
added to each well. The negative control group was prepared by
adding colchicine without any reversing compounds, while verap-
amil was used as a positive control. After incubated for 48 h, cells
were stained using MTT method described in Section 4.3.2. IC50
SIMS (negative) m/z 945.5109 [MꢂH]ꢂ (calcd for C53H73N2O13
,
945.5113).

J. Xiong et al. / Bioorg. Med. Chem. 18 (2010) 2964–2975
2975
10. Ozben, T. FEBS Lett. 2006, 580, 2903.
values of colchicine in the presence of each test compound were
calculated using the concentration–inhibition curve.
11. Tsuruo, T.; Lida, H.; Tsukagoshi, S.; Sakurai, Y. Cancer Res. 1981, 41, 1967.
12. Futscher, B. W.; Foley, N. E.; Guzman, M. C. G.; Meltzer, P. S.; Sullivan, D. M. Int.
J. Cancer 1996, 66, 520.
13. Robert, J.; Jarry, C. J. Med. Chem. 2003, 46, 4805.
14. Relling, M. V. Ther. Drug. Monit. 1996, 18, 350.
References and notes
15. Benet, L. Z.; Cummins, C. L.; Wu, C. Y. Int. J. Pharm. 2004, 277, 3.
16. Kashiwada, Y.; Sekiya, M.; Yamazaki, K.; Ikeshiro, Y.; Fujioka, T.; Yamagishi, T.;
Kitagawa, S.; Takaishi, Y. J. Nat. Prod. 2007, 70, 623.
17. Wiese, M.; Pajeva, I. K. Curr. Med. Chem. 2001, 8, 685.
18. Pajeva, I. K.; Wiese, M. J. Med. Chem. 2002, 45, 5671.
19. Ramalhete, C.; Molnar, J.; Mulhovo, S.; Rosario, V. E.; Ferreira, M. J. U. Bioorg.
Med. Chem. 2009, 17, 6942.
20. Jiao, W.; Dong, W. W.; Li, Z. F.; Deng, M. C.; Lu, R. H. Bioorg. Med. Chem. 2009, 17,
4786.
21. Stouch, T. R.; Gudmundsson, O. Adv. Drug Deliv. Rev. 2002, 54, 315.
22. Taipale, H. T.; Vepsalainen, J.; Laatikainen, R.; Reichardt, P. B.; Lapinjoki, S. P.
Phytochemistry 1993, 34, 755.
23. Prokof’eva, N. G.; Anisimov, M. M.; Shentsova, E. B.; Pokhilo, N. D. Planta Med.
2004, 70, 476.
24. Mosmann, T. J. Immunol. Methods 1983, 65, 55.
25. Carmichael, J.; Degraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Cancer
Res. 1987, 47, 936.
1. Gottesman, M. M.; Fojo, T.; Bates, S. E. Nat. Rev. Cancer 2002, 2, 48.
2. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Genthe, C. B.; Gottesman, M. M. Nat.
Rev. Drug Disc. 2006, 5, 219.
3. Schinkel, A. H.; Smit, J. J. M.; Van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.;
Deemter, L.; van Mol, C. A. A. M.; Valk, M. A.; van der Robanus-Maandag, E. C.;
Te Riele, H. P. J.; Berns, A. J. M.; Borst, P. Cell 1994, 77, 491.
4. Schinkel, A. H.; Mayer, U.; Wagenaa, E.; Mol, C. A. A. M.; Van Deemter, L.; Smit,
J. J. M.; Valk, M. A.; van der Voordouw, A. C.; Spits, H.; Van Tellingen, O.;
Zijlmans, J. M.; Fibbe, W. E.; Borst, P. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4028.
5. Tian, Q.; Zhang, J.; Chan, E.; Duan, W.; Zhou, S. F. Drug Dev. Res. 2005, 64, 1.
6. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R. P.; Harrell, P. M.;
Trinh, Y. T.; Zhang, Q. H.; Urbatsch, I. L.; Geoffrey, C. Science 2009, 323, 1718.
7. Ling, V. Cancer 1992, 69, 2603.
8. Ambudkar, S. V.; Dey, S.; Hrycyna, C. A.; Ramachandra, M.; Pastan, I.;
Gottesman, M. M. Annu. Rev. Pharmacol. Toxicol. 1999, 39, 361.
9. Boumendjel, A.; Baubichon-Cortay, H.; Trompier, D.; Perrotton, T.; Pietro, A. D.
Med. Res. Rev. 2005, 25, 453.